Oil States Announces Second Quarter 2023 Results

Oil States Announces Second Quarter 2023 Results

  • Net income of $0.6 million, or $0.01 per diluted share, reported for the quarter

  • Revenue of $183.5 million, while down 6% sequentially, increased 1% year-over-year

  • Adjusted EBITDA (a non-GAAP measure(1)) of $19.0 million decreased $2.4 million sequentially but increased $2.0 million year-over-year

  • Generated operating cash flow of $44.7 million in the quarter

  • Offshore/Manufactured Products segment’s backlog increased sequentially for a fourth consecutive quarter totaling $338 million as of June 30, with a quarterly book-to-bill ratio of 1.1x

  • Invested $3.0 million in share repurchases

HOUSTON–(BUSINESS WIRE)–
Oil States International, Inc. (NYSE: OIS):

 

Three Months Ended

 

% Change

(Unaudited, In Thousands, Except Per Share Amounts)

June 30,

2023

 

March 31,

2023

 

June 30,

2022

 

Sequential

 

Year-over-Year

Consolidated results:

 

 

 

 

 

 

 

 

 

Revenues

$

183,529

 

 

$

196,199

 

 

$

181,834

 

 

(6

)%

 

1%

Operating income (loss)

$

3,269

 

 

$

5,875

 

 

$

(1,090

)

 

(44

)%

 

nm

Net income (loss)

$

558

 

 

$

2,158

 

 

$

(5,144

)

 

(74

)%

 

nm

Diluted earning per share

$

0.01

 

 

$

0.03

 

 

$

(0.08

)

 

(67

)%

 

nm

Adjusted EBITDA(1)

$

19,016

 

 

$

21,407

 

 

$

16,988

 

 

(11

)%

 

12%

 

 

 

 

 

 

 

 

 

 

Revenues by segment:

 

 

 

 

 

 

 

 

 

Offshore/Manufactured Products

$

94,086

 

 

$

98,199

 

 

$

96,467

 

 

(4

)%

 

(2)%

Well Site Services

 

64,536

 

 

 

67,058

 

 

 

54,819

 

 

(4

)%

 

18%

Downhole Technologies

 

24,907

 

 

 

30,942

 

 

 

30,548

 

 

(20

)%

 

(18)%

 

 

 

 

 

 

 

 

 

 

Operating income (loss) by segment:

 

 

 

 

 

 

 

 

 

Offshore/Manufactured Products

$

11,253

 

 

$

11,090

 

 

$

9,441

 

 

1

%

 

19 %

Well Site Services

 

4,732

 

 

 

6,966

 

 

 

601

 

 

(32

)%

 

nm

Downhole Technologies

 

(2,536

)

 

 

(1,519

)

 

 

(1,485

)

 

(67

)%

 

(71)%

 

 

 

 

 

 

 

 

 

 

Adjusted Segment EBITDA (a non-GAAP measure(1)):

Offshore/Manufactured Products

$

15,981

 

 

$

15,923

 

 

$

14,735

 

 

%

 

8 %

Well Site Services

 

11,425

 

 

 

13,223

 

 

 

8,874

 

 

(14

)%

 

29 %

Downhole Technologies

 

1,639

 

 

 

2,756

 

 

 

2,854

 

 

(41

)%

 

(43)%

___________________

(1)

Adjusted EBITDA and Adjusted Segment EBITDA are non-GAAP measures, see “Reconciliations of GAAP to Non-GAAP Financial Information” tables below for reconciliations to their most comparable GAAP measures as well as further clarification and explanation.

Oil States International, Inc. reported net income of $0.6 million, or $0.01 per share, for the second quarter of 2023 on revenues of $183.5 million and Adjusted EBITDA of $19.0 million. These results compare to revenues of $196.2 million, net income of $2.2 million, or $0.03 per share, and Adjusted EBITDA of $21.4 million reported in the first quarter of 2023.

Oil States’ President and Chief Executive Officer, Cindy B. Taylor, stated,

“Our reported second quarter results reflect the dueling trends of activity declines in U.S. shale basins with offsetting growth in offshore and international regions. Despite sequentially weaker second quarter revenues and Adjusted EBITDA, we confirm our full-year guidance of $92 to $100 million of Adjusted EBITDA based upon expected contributions from the ongoing recovery in offshore activity. Our forecast is supported by the backlog growth that we have witnessed at our Offshore/Manufactured Products segment, which increased to $338 million in the second quarter of 2023 – a quarter-end level last observed at the end of 2015.

“We generated very strong cash flow from operations of $45 million in the second quarter, invested $11 million in capital equipment, repurchased $3 million of our common stock and repaid all amounts outstanding under the revolving credit facility. With cash on-hand of $42 million and no significant debt maturities until 2026, we are in a strong position to create stockholder value.

“We remain encouraged by the continued recovery in offshore activity coupled with future benefits to be gained from new product introductions.”

Business Segment Results

(See Segment Data and Adjusted Segment EBITDA tables below)

Offshore/Manufactured Products

Offshore/Manufactured Products reported revenues of $94.1 million, operating income of $11.3 million and Adjusted Segment EBITDA of $16.0 million in the second quarter of 2023, compared to revenues of $98.2 million, operating income of $11.1 million and Adjusted Segment EBITDA of $15.9 million reported in the first quarter of 2023. Adjusted Segment EBITDA margin in the second quarter of 2023 was 17%, compared to 16% in the prior quarter.

Backlog totaled $338 million as of June 30, 2023, an increase of $12 million, or 4%, from March 31, 2023 and $97 million, or 40%, from June 30, 2022. The current quarter-end backlog is at its highest level since December 31, 2015. Second quarter 2023 bookings totaled $106 million, yielding a quarterly book-to-bill ratio of 1.1x (1.2x year-to-date).

Well Site Services

Well Site Services reported revenues of $64.5 million, operating income of $4.7 million and Adjusted Segment EBITDA of $11.4 million in the second quarter of 2023, compared to revenues of $67.1 million, operating income of $7.0 million and Adjusted Segment EBITDA of $13.2 million reported in the first quarter of 2023. Adjusted Segment EBITDA margin was 18% in the second quarter of 2023, compared to 20% in the first quarter of 2023.

Downhole Technologies

Downhole Technologies reported revenues of $24.9 million, an operating loss of $2.5 million and Adjusted Segment EBITDA of $1.6 million in the second quarter of 2023, compared to revenues of $30.9 million, an operating loss of $1.5 million and Adjusted Segment EBITDA of $2.8 million reported in the first quarter of 2023. The segment’s second quarter operating results included a $1.0 million non-cash provision for excess and obsolete inventory. Adjusted Segment EBITDA margin in the second quarter of 2023 was 7%, compared to 9% in the first quarter of 2023.

Corporate

Corporate operating expenses in the second quarter of 2023 totaled $10.2 million.

Interest Expense, Net

Net interest expense totaled $2.1 million in the second quarter of 2023, which included $0.4 million of non-cash amortization of deferred debt issuance costs.

Income Taxes

The Company recognized tax expense of $0.9 million on pre-tax income of $1.4 million during the second quarter of 2023. In the first quarter of 2023, the Company recognized a tax expense of $1.6 million on pre-tax income of $3.8 million.

Cash Flows

During the second quarter of 2023, the Company generated cash flows from operations of $44.7 million and invested $10.8 million in new equipment to support future growth.

The Company also repurchased 439 thousand shares of its common stock for $3.0 million in the second quarter of 2023. A total of $22.0 million remains available under the share repurchase authorization, which extends through February 2025.

Financial Condition

No borrowings were outstanding under the Company’s asset-based revolving credit facility (the “ABL Facility”) at June 30, 2023. Cash on-hand increased from $15.8 million at March 31, 2023 to $42.4 million at June 30, 2023. Liquidity (cash plus borrowing availability) totaled $133.4 million at June 30, 2023, with amounts available to be drawn under the ABL Facility totaling $90.9 million.

Conference Call Information

The call is scheduled for July 27, 2023 at 10 a.m. Central Daylight Time, is being webcast and can be accessed from the Company’s website at www.ir.oilstatesintl.com. Participants may also join the conference call by dialing 1 (888) 210-3346 in the United States or by dialing +1 (646) 960-0253 internationally and using the passcode 7534957. A replay of the conference call will be available approximately two hours after the completion of the call and can be accessed from the Company’s website at www.ir.oilstatesintl.com.

About Oil States

Oil States International, Inc. is a global provider of manufactured products and services to customers in the energy, industrial and military sectors. The Company’s manufactured products include highly engineered capital equipment and consumable products. Oil States is headquartered in Houston, Texas with manufacturing and service facilities strategically located across the globe. Oil States is publicly traded on the New York Stock Exchange under the symbol “OIS”.

For more information on the Company, please visit Oil States International’s website at www.oilstatesintl.com.

Cautionary Language Concerning Forward Looking Statements

The foregoing contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those that do not state historical facts and are, therefore, inherently subject to risks and uncertainties. The forward-looking statements included herein are based on current expectations and entail various risks and uncertainties that could cause actual results to differ materially from those forward-looking statements. Such risks and uncertainties include, among others, the level of supply and demand for oil and natural gas, fluctuations in the current and future prices of oil and natural gas, the level of exploration, drilling and completion activity, general global economic conditions, the cyclical nature of the oil and natural gas industry, geopolitical tensions, the financial health of our customers, the actions of the Organization of Petroleum Exporting Countries (“OPEC”) and other producing nations with respect to crude oil production levels and pricing, the impact of environmental matters, including executive actions and regulatory efforts to adopt environmental or climate change regulations that may result in increased operating costs or reduced oil and natural gas production or demand globally, our ability to access and the cost of capital in the bank and capital markets, our ability to develop new competitive technologies and products, and other factors discussed in the “Business” and “Risk Factors” sections of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the subsequently filed Quarterly Report on Form 10-Q and Periodic Reports on Form 8-K. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof, and, except as required by law, the Company undertakes no obligation to update those statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments.

OIL STATES INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In Thousands, Except Per Share Amounts)

(Unaudited)

 

Three Months Ended

 

Six Months Ended

 

June 30,

2023

 

March 31, 2023

 

June 30,

2022

 

June 30,

2023

 

June 30,

2022

Revenues:

 

 

 

 

 

 

 

 

 

Products

$

92,630

 

 

$

99,840

 

 

$

99,033

 

 

$

192,470

 

 

$

184,794

 

Services

 

90,899

 

 

 

96,359

 

 

 

82,801

 

 

 

187,258

 

 

 

161,084

 

 

 

183,529

 

 

 

196,199

 

 

 

181,834

 

 

 

379,728

 

 

 

345,878

 

 

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

 

 

Product costs

 

72,659

 

 

 

78,677

 

 

 

79,388

 

 

 

151,336

 

 

 

144,189

 

Service costs

 

69,371

 

 

 

72,058

 

 

 

62,768

 

 

 

141,429

 

 

 

124,571

 

Cost of revenues (exclusive of depreciation and amortization expense presented below)

 

142,030

 

 

 

150,735

 

 

 

142,156

 

 

 

292,765

 

 

 

268,760

 

Selling, general and administrative expense

 

23,528

 

 

 

24,016

 

 

 

23,757

 

 

 

47,544

 

 

 

47,590

 

Depreciation and amortization expense

 

15,537

 

 

 

15,256

 

 

 

17,239

 

 

 

30,793

 

 

 

35,056

 

Other operating (income) expense, net

 

(835

)

 

 

317

 

 

 

(228

)

 

 

(518

)

 

 

(102

)

 

 

180,260

 

 

 

190,324

 

 

 

182,924

 

 

 

370,584

 

 

 

351,304

 

Operating income (loss)

 

3,269

 

 

 

5,875

 

 

 

(1,090

)

 

 

9,144

 

 

 

(5,426

)

 

 

 

 

 

 

 

 

 

 

Interest expense, net

 

(2,059

)

 

 

(2,391

)

 

 

(2,638

)

 

 

(4,450

)

 

 

(5,310

)

Other income, net

 

210

 

 

 

276

 

 

 

376

 

 

 

486

 

 

 

1,401

 

Income (loss) before income taxes

 

1,420

 

 

 

3,760

 

 

 

(3,352

)

 

 

5,180

 

 

 

(9,335

)

Income tax provision

 

(862

)

 

 

(1,602

)

 

 

(1,792

)

 

 

(2,464

)

 

 

(5,233

)

Net income (loss)

$

558

 

 

$

2,158

 

 

$

(5,144

)

 

$

2,716

 

 

$

(14,568

)

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share:

 

 

 

 

 

 

 

 

 

Basic

$

0.01

 

 

$

0.03

 

 

$

(0.08

)

 

$

0.04

 

 

$

(0.24

)

Diluted

 

0.01

 

 

 

0.03

 

 

 

(0.08

)

 

 

0.04

 

 

 

(0.24

)

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding:

 

 

 

 

 

 

 

 

Basic

 

62,803

 

 

 

62,825

 

 

 

60,704

 

 

 

62,814

 

 

 

60,601

 

Diluted

 

63,174

 

 

 

63,072

 

 

 

60,704

 

 

 

63,161

 

 

 

60,601

 

 

OIL STATES INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In Thousands)

 

June 30, 2023

 

December 31, 2022

 

(Unaudited)

 

 

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

42,420

 

 

$

42,018

 

Accounts receivable, net

 

180,917

 

 

 

218,769

 

Inventories, net

 

205,132

 

 

 

182,658

 

Prepaid expenses and other current assets

 

28,217

 

 

 

19,317

 

Total current assets

 

456,686

 

 

 

462,762

 

 

 

 

 

Property, plant, and equipment, net

 

296,015

 

 

 

303,835

 

Operating lease assets, net

 

23,266

 

 

 

23,028

 

Goodwill, net

 

79,778

 

 

 

79,282

 

Other intangible assets, net

 

161,476

 

 

 

169,798

 

Other noncurrent assets

 

27,799

 

 

 

25,687

 

Total assets

$

1,045,020

 

 

$

1,064,392

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Current portion of long-term debt

$

513

 

 

$

17,831

 

Accounts payable

 

56,726

 

 

 

73,251

 

Accrued liabilities

 

42,987

 

 

 

49,057

 

Current operating lease liabilities

 

6,750

 

 

 

6,142

 

Income taxes payable

 

2,740

 

 

 

2,605

 

Deferred revenue

 

53,027

 

 

 

44,790

 

Total current liabilities

 

162,743

 

 

 

193,676

 

 

 

 

 

Long-term debt

 

135,273

 

 

 

135,066

 

Long-term operating lease liabilities

 

20,027

 

 

 

20,658

 

Deferred income taxes

 

8,601

 

 

 

6,652

 

Other noncurrent liabilities

 

20,271

 

 

 

18,782

 

Total liabilities

 

346,915

 

 

 

374,834

 

 

 

 

 

Stockholders’ equity:

 

 

 

Common stock

 

772

 

 

 

766

 

Additional paid-in capital

 

1,125,647

 

 

 

1,122,292

 

Retained earnings

 

274,743

 

 

 

272,027

 

Accumulated other comprehensive loss

 

(71,522

)

 

 

(78,941

)

Treasury stock

 

(631,535

)

 

 

(626,586

)

Total stockholders’ equity

 

698,105

 

 

 

689,558

 

Total liabilities and stockholders’ equity

$

1,045,020

 

 

$

1,064,392

 

OIL STATES INTERNATIONAL, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In Thousands)

(Unaudited)

 

Six Months Ended June 30,

 

2023

 

2022

Cash flows from operating activities:

 

 

 

Net income (loss)

$

2,716

 

 

$

(14,568

)

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

 

 

 

Depreciation and amortization expense

 

30,793

 

 

 

35,056

 

Stock-based compensation expense

 

3,361

 

 

 

3,504

 

Amortization of deferred financing costs

 

892

 

 

 

944

 

Deferred income tax provision

 

997

 

 

 

2,584

 

Gains on disposals of assets

 

(561

)

 

 

(1,185

)

Settlement of disputes with seller of GEODynamics, Inc.

 

 

 

 

620

 

Other, net

 

(267

)

 

 

360

 

Changes in operating assets and liabilities, net of effect from acquired business:

 

 

 

Accounts receivable

 

39,042

 

 

 

(20,469

)

Inventories

 

(21,197

)

 

 

(14,664

)

Accounts payable and accrued liabilities

 

(25,924

)

 

 

(5,994

)

Deferred revenue

 

8,237

 

 

 

4,647

 

Other operating assets and liabilities, net

 

653

 

 

 

(870

)

Net cash flows provided by (used in) operating activities

 

38,742

 

 

 

(10,035

)

 

 

 

 

Cash flows from investing activities:

 

 

 

Capital expenditures

 

(17,338

)

 

 

(6,453

)

Proceeds from disposition of property and equipment

 

690

 

 

 

1,652

 

Acquisition of business, net of cash acquired

 

 

 

 

(8,125

)

Other, net

 

(66

)

 

 

(85

)

Net cash flows used in investing activities

 

(16,714

)

 

 

(13,011

)

 

 

 

 

Cash flows from financing activities:

 

 

 

Revolving credit facility borrowings

 

35,592

 

 

 

9,725

 

Revolving credit facility repayments

 

(35,592

)

 

 

(9,725

)

Repayment of 1.50% convertible senior notes

 

(17,315

)

 

 

(6,272

)

Other debt and finance lease repayments

 

(226

)

 

 

(359

)

Payment of financing costs

 

(95

)

 

 

(74

)

Purchases of treasury stock

 

(3,001

)

 

 

 

Shares added to treasury stock as a result of net share settlements

due to vesting of stock awards

 

(1,948

)

 

 

(1,002

)

Net cash flows used in financing activities

 

(22,585

)

 

 

(7,707

)

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents

 

959

 

 

 

147

 

Net change in cash and cash equivalents

 

402

 

 

 

(30,606

)

Cash and cash equivalents, beginning of period

 

42,018

 

 

 

52,852

 

Cash and cash equivalents, end of period

$

42,420

 

 

$

22,246

 

 

 

 

 

Cash paid (received) for:

 

 

 

Interest

$

4,060

 

 

$

4,105

 

Income taxes, net

 

(1,475

)

 

 

291

 

 

OIL STATES INTERNATIONAL, INC. AND SUBSIDIARIES

SEGMENT DATA

(In Thousands)

(Unaudited)

 

Three Months Ended

 

Six Months Ended

 

June 30,

2023

 

March 31,

2023

 

June 30,

2022

 

June 30,

2023

 

June 30,

2022

Revenues(1):

 

 

 

 

 

 

 

 

 

Offshore/Manufactured Products

 

 

 

 

 

 

 

 

 

Project-driven:

 

 

 

 

 

 

 

 

 

Products

$

32,210

 

 

$

39,132

 

 

$

41,098

 

 

$

71,342

 

 

$

74,942

 

Services

 

24,846

 

 

 

24,630

 

 

 

23,995

 

 

 

49,476

 

 

 

48,293

 

 

 

57,056

 

 

 

63,762

 

 

 

65,093

 

 

 

120,818

 

 

 

123,235

 

Military and other products

 

7,965

 

 

 

6,997

 

 

 

7,763

 

 

 

14,962

 

 

 

13,109

 

Short-cycle products

 

29,065

 

 

 

27,440

 

 

 

23,611

 

 

 

56,505

 

 

 

44,235

 

Total Offshore/Manufactured Products

 

94,086

 

 

 

98,199

 

 

 

96,467

 

 

 

192,285

 

 

 

180,579

 

Well Site Services

 

64,536

 

 

 

67,058

 

 

 

54,819

 

 

 

131,594

 

 

 

102,991

 

Downhole Technologies

 

24,907

 

 

 

30,942

 

 

 

30,548

 

 

 

55,849

 

 

 

62,308

 

Total revenues

$

183,529

 

 

$

196,199

 

 

$

181,834

 

 

$

379,728

 

 

$

345,878

 

 

 

 

 

 

 

 

 

 

 

Operating income (loss):

 

 

 

 

 

 

 

 

 

Offshore/Manufactured Products

$

11,253

 

 

$

11,090

 

 

$

9,441

 

 

$

22,343

 

 

$

19,637

 

Well Site Services

 

4,732

 

 

 

6,966

 

 

 

601

 

 

 

11,698

 

 

 

(2,794

)

Downhole Technologies

 

(2,536

)

 

 

(1,519

)

 

 

(1,485

)

 

 

(4,055

)

 

 

(2,990

)

Corporate

 

(10,180

)

 

 

(10,662

)

 

 

(9,647

)

 

 

(20,842

)

 

 

(19,279

)

Total operating income (loss)

$

3,269

 

 

$

5,875

 

 

$

(1,090

)

 

$

9,144

 

 

$

(5,426

)

________________

(1)

The Company revised its supplemental disclosure of disaggregated revenue information in the second quarter of 2023. Prior-period disclosures of disaggregated revenue information were conformed with the current-period presentation.

OIL STATES INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL INFORMATION

ADJUSTED EBITDA (A)

(In Thousands)

(Unaudited)

 

Three Months Ended

 

Six Months Ended

 

June 30,

2023

 

March 31,

2023

 

June 30,

2022

 

June 30,

2023

 

June 30,

2022

 

 

 

 

 

 

 

 

 

 

Net income (loss)

$

558

 

$

2,158

 

$

(5,144

)

 

$

2,716

 

$

(14,568

)

Interest expense, net

 

2,059

 

 

2,391

 

 

2,638

 

 

 

4,450

 

 

5,310

 

Income tax provision

 

862

 

 

1,602

 

 

1,792

 

 

 

2,464

 

 

5,233

 

Depreciation and amortization expense

 

15,537

 

 

15,256

 

 

17,239

 

 

 

30,793

 

 

35,056

 

Settlement of disputes with seller of GEODynamics, Inc.

 

 

 

 

 

620

 

 

 

 

 

620

 

Gains on extinguishment of 1.50% convertible senior notes

 

 

 

 

 

(157

)

 

 

 

 

(157

)

Adjusted EBITDA

$

19,016

 

$

21,407

 

$

16,988

 

 

$

40,423

 

$

31,494

 

________________

(A)

The term Adjusted EBITDA consists of net income (loss) plus net interest expense, taxes, depreciation and amortization expense, and loss on settlement of disputes with the seller of GEODynamics, Inc., less gains on extinguishment of 1.50% convertible senior notes (the “2023 Notes”). Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles (“GAAP”) and should not be considered in isolation from or as a substitute for net income (loss) or cash flow measures prepared in accordance with GAAP or as a measure of profitability or liquidity. Additionally, Adjusted EBITDA may not be comparable to other similarly titled measures of other companies. The Company has included Adjusted EBITDA as a supplemental disclosure because its management believes that Adjusted EBITDA provides useful information regarding its ability to service debt and to fund capital expenditures and provides investors a helpful measure for comparing its operating performance with the performance of other companies that have different financing and capital structures or tax rates. The Company uses Adjusted EBITDA to compare and to monitor the performance of the Company and its business segments to other comparable public companies and as a benchmark for the award of incentive compensation under its annual incentive compensation plan. The table above sets forth reconciliations of Adjusted EBITDA to net income (loss), which is the most directly comparable measure of financial performance calculated under GAAP.

OIL STATES INTERNATIONAL, INC. AND SUBSIDIARIES

RECONCILIATIONS OF GAAP TO NON-GAAP FINANCIAL INFORMATION

ADJUSTED SEGMENT EBITDA (B)

(In Thousands)

(Unaudited)

 

Three Months Ended

 

Six Months Ended

 

June 30,

2023

 

March 31,

2023

 

June 30,

2022

 

June 30,

2023

 

June 30,

2022

Offshore/Manufactured Products:

 

 

 

 

 

 

 

 

 

Operating income

$

11,253

 

 

$

11,090

 

 

$

9,441

 

 

$

22,343

 

 

$

19,637

 

Other income, net

 

81

 

 

 

165

 

 

 

45

 

 

 

246

 

 

 

86

 

Depreciation and amortization expense

 

4,647

 

 

 

4,668

 

 

 

5,249

 

 

 

9,315

 

 

 

10,579

 

Adjusted Segment EBITDA

$

15,981

 

 

$

15,923

 

 

$

14,735

 

 

$

31,904

 

 

$

30,302

 

 

 

 

 

 

 

 

 

 

 

Well Site Services:

 

 

 

 

 

 

 

 

 

Operating income (loss)

$

4,732

 

 

$

6,966

 

 

$

601

 

 

$

11,698

 

 

$

(2,794

)

Other income, net

 

129

 

 

 

111

 

 

 

878

 

 

 

240

 

 

 

1,864

 

Depreciation and amortization expense

 

6,564

 

 

 

6,146

 

 

 

7,395

 

 

 

12,710

 

 

 

15,327

 

Adjusted Segment EBITDA

$

11,425

 

 

$

13,223

 

 

$

8,874

 

 

$

24,648

 

 

$

14,397

 

 

 

 

 

 

 

 

 

 

 

Downhole Technologies:

 

 

 

 

 

 

 

 

 

Operating loss

$

(2,536

)

 

$

(1,519

)

 

$

(1,485

)

 

$

(4,055

)

 

$

(2,990

)

Other expense, net

 

 

 

 

 

 

 

(84

)

 

 

 

 

 

(86

)

Depreciation and amortization expense

 

4,175

 

 

 

4,275

 

 

 

4,423

 

 

 

8,450

 

 

 

8,807

 

Adjusted Segment EBITDA

$

1,639

 

 

$

2,756

 

 

$

2,854

 

 

$

4,395

 

 

$

5,731

 

 

 

 

 

 

 

 

 

 

 

Corporate:

 

 

 

 

 

 

 

 

 

Operating loss

$

(10,180

)

 

$

(10,662

)

 

$

(9,647

)

 

$

(20,842

)

 

$

(19,279

)

Other expense, net

 

 

 

 

 

 

 

(463

)

 

 

 

 

 

(463

)

Depreciation and amortization expense

 

151

 

 

 

167

 

 

 

172

 

 

 

318

 

 

 

343

 

Settlement of disputes with seller of GEODynamics, Inc.

 

 

 

 

 

 

 

620

 

 

 

 

 

 

620

 

Gains on extinguishment of 1.50% convertible senior notes

 

 

 

 

 

 

 

(157

)

 

 

 

 

 

(157

)

Adjusted Segment EBITDA

$

(10,029

)

 

$

(10,495

)

 

$

(9,475

)

 

$

(20,524

)

 

$

(18,936

)

________________

(B)

The term Adjusted Segment EBITDA consists of operating income (loss) plus other income (expense), depreciation and amortization expense, and loss on settlement of disputes with the seller of GEODynamics, Inc., less gains on extinguishment of the 2023 Notes. Adjusted Segment EBITDA is not a measure of financial performance under GAAP and should not be considered in isolation from or as a substitute for operating income (loss) or cash flow measures prepared in accordance with GAAP or as a measure of profitability or liquidity. Additionally, Adjusted Segment EBITDA may not be comparable to other similarly titled measures of other companies. The Company has included Adjusted Segment EBITDA as supplemental disclosure because its management believes that Adjusted Segment EBITDA provides useful information regarding its ability to service debt and to fund capital expenditures and provides investors a helpful measure for comparing its operating performance with the performance of other companies that have different financing and capital structures or tax rates. The Company uses Adjusted Segment EBITDA to compare and to monitor the performance of its business segments to other comparable public companies and as a benchmark for the award of incentive compensation under its annual incentive compensation plan. The table above sets forth reconciliations of Adjusted Segment EBITDA to operating income (loss), which is the most directly comparable measure of financial performance calculated under GAAP.

 

Company Contact:

Lloyd A. Hajdik

Oil States International, Inc.

Executive Vice President, Chief Financial Officer and Treasurer

(713) 652-0582

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Energy Defense Military Oil/Gas

MEDIA:

Laser Photonics’ DefenseTech MLRI-2000 Is the Perfect Tool for MRO in the Defense Industry

Laser Photonics’ DefenseTech MLRI-2000 Is the Perfect Tool for MRO in the Defense Industry

ORLANDO, Fla.–(BUSINESS WIRE)–
Laser Photonics Corporation (NASDAQ: LASE), a leading global industrial developer of CleanTech laser systems for laser cleaning, has recently launched its DefenseTech Missile Laser Rust Inhibitor (MLRI) 2000 laser system.

“Corrosion is an issue that continues to plague the defense industry and the MLRI-2000 is the perfect solution to this problem,” said Wayne Tupuola, chief executive officer of Laser Photonics. “With this product, industry professionals can effectively prolong the lifespan and performance of missiles and other equipment.”

The MLRI-2000 laser cleaning system created by Laser Photonics is the ideal solution to the military and defense industry’s unique maintenance-related challenges. This technology is able to remove corrosion and rust from the surface of missiles and other equipment without damaging the underlying material. Corrosion is a multibillion-dollar issue that affects military readiness by taking critical weapon systems out of action and creating safety hazards. With the MLRI-2000, operators can tackle all of this while eliminating the health and safety concerns that come with using traditional methods.

Missile Laser Rust Inhibitor LPC-MLRI

The MLRI is a handheld laser cleaning machine and surface preparation system designed to remove rust, paint, and other elements from a variety of surface types. Laser Photonics DefenseTech cleaning equipment provides a safe and effective solution for all branches of the military to maintain and operate vehicles, aircraft, ships, equipment and more. Laser cleaning is faster, safer, and more efficient than traditional cleaning methods.

About Laser Photonics Corporation

Laser Photonics is a vertically-integrated manufacturer and R&D Center of Excellence for industrial laser technologies and systems. LPC seeks to disrupt the $46 billion, centuries old, sand and abrasives blasting markets, focusing on surface cleaning, rust removal, corrosion control, de-painting and other laser-based industrial applications. LPC’s new generation of leading-edge laser blasting technologies and equipment also addresses the numerous health, safety, environmental, and regulatory issues associated with the old methods. As a result, LPC has quickly gained a reputation as an industry leader for industrial laser systems with a brand that stands for quality, technology and product innovation. Currently, world-renowned and Fortune 1000 manufacturers in the aerospace, automotive, defense, energy, industrial, maritime, space exploration and shipbuilding industries are using LPC’s “unique-to-industry” systems. For more information, visit www.laserphotonics.com.

David Thierer

Marketing Specialist

Laser Photonics Corporation

[email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Other Manufacturing Technology Other Defense Construction & Property Other Technology Manufacturing Machinery Electronic Design Automation Other Construction & Property Defense

MEDIA:

Logo
Logo

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial

Data support ongoing discussions with global health authorities

WILMINGTON, Del.–(BUSINESS WIRE)–
High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients across multiple HER2-expressing advanced solid tumors, two secondary endpoints of the trial.

In the primary analysis, ENHERTUcontinued to show durable responses based on investigator-assessed confirmed objective response rate (ORR), the primary endpoint of the trial, and duration of response (DoR), a secondary endpoint; reinforcing results from an interim analysis of the trial recently presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

Cristian Massacesi, Chief Medical Officer and Oncology Chief Development Officer, AstraZeneca, said: “The progression-free survival and overall survival results for ENHERTU alongside the continued robust and durable tumor responses seen with further follow up underscore the potential value of this important medicine for patients with HER2-expressing cancers who currently have no targeted treatment options. With a high unmet need in these cancers, we are working with health authorities to bring ENHERTU to patients with HER2-expressing cancers that could potentially benefit from this medicine as quickly as possible.”

Mark Rutstein, Global Head, Oncology Development, Daiichi Sankyo, said: “These updated results from the DESTINY-PanTumor02 trial are important as we work to reshape the clinical landscape in HER2-expressing advanced cancers, where patients currently have limited treatment options and face a poor prognosis. The overall survival demonstrated by ENHERTU in these patients is a significant step forward in the potential to advance current standards of care and offer new options for patients with HER2-expressing cancers.”

The DESTINY-PanTumor02 Phase II trial is evaluating the efficacy and safety of ENHERTU in patients with previously treated locally advanced, unresectable, or metastatic HER2-expressing solid tumors not eligible for curative therapy, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and other cancers.

The safety profile observed in the primary analysis was consistent with prior data and with other trials of ENHERTU with no new safety concerns identified. Interstitial lung disease (ILD) rates and severity were consistent with those observed in other trials of ENHERTU, with a low rate of Grade 5 ILD events observed as determined by an independent adjudication committee.

These data will be presented at a forthcoming medical meeting and will support ongoing discussions with global health authorities.

Important Safety Information

Indications

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with:

  • Unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:

    – In the metastatic setting, or

    – In the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy
  • Unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy

  • Unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy

    This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

  • Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen

 
WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY
  • Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.
  • Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.

Contraindications

None.

Warnings and Precautions

Interstitial Lung Disease / Pneumonitis

Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≤28 days from date of onset, maintain dose. If resolved in >28 days from date of onset, reduce dose one level. Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥0.5 mg/kg/day prednisolone or equivalent). For symptomatic ILD/pneumonitis (Grade 2 or greater), permanently discontinue ENHERTU. Promptly initiate systemic corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥1 mg/kg/day prednisolone or equivalent) and continue for at least 14 days followed by gradual taper for at least 4 weeks.

Metastatic Breast Cancer and HER2-Mutant NSCLC (5.4 mg/kg)

In patients with metastatic breast cancer and HER2-mutant NSCLC treated with ENHERTU 5.4 mg/kg, ILD occurred in 12% of patients. Fatal outcomes due to ILD and/or pneumonitis occurred in 1.0% of patients treated with ENHERTU. Median time to first onset was 5 months (range: 0.9 to 23).

Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)

In patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, ILD occurred in 10% of patients. Median time to first onset was 2.8 months (range: 1.2 to 21).

Neutropenia

Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. For Grade 3 neutropenia (Absolute Neutrophil Count [ANC] <1.0 to 0.5 x 109/L), interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose. For Grade 4 neutropenia (ANC <0.5 x 109/L), interrupt ENHERTU until resolved to Grade 2 or less, then reduce dose by one level. For febrile neutropenia (ANC <1.0 x 109/L and temperature >38.3º C or a sustained temperature of ≥38º C for more than 1 hour), interrupt ENHERTU until resolved, then reduce dose by one level.

Metastatic Breast Cancer and HER2-Mutant NSCLC (5.4 mg/kg)

In patients with metastatic breast cancer and HER2-mutant NSCLC treated with ENHERTU 5.4 mg/kg, a decrease in neutrophil count was reported in 65% of patients. Sixteen percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 22 days (range: 2 to 664). Febrile neutropenia was reported in 1.1% of patients.

Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)

In patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, a decrease in neutrophil count was reported in 72% of patients. Fifty-one percent had Grade 3 or 4 decreased neutrophil count. Median time to first onset of decreased neutrophil count was 16 days (range: 4 to 187). Febrile neutropenia was reported in 4.8% of patients.

Left Ventricular Dysfunction

Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including ENHERTU. Assess LVEF prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage LVEF decrease through treatment interruption. When LVEF is >45% and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is <10%, continue treatment with ENHERTU and repeat LVEF assessment within 3 weeks. When LVEF is 40-45% and absolute decrease from baseline is 10-20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU. If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. When LVEF is <40% or absolute decrease from baseline is >20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF of <40% or absolute decrease from baseline of >20% is confirmed, permanently discontinue ENHERTU. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF <50% prior to initiation of treatment.

Metastatic Breast Cancer and HER2-Mutant NSCLC (5.4 mg/kg)

In patients with metastatic breast cancer and HER2-mutant NSCLC treated with ENHERTU 5.4 mg/kg, LVEF decrease was reported in 3.6% of patients, of which 0.4% were Grade 3.

Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)

In patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg, no clinical adverse events of heart failure were reported; however, on echocardiography, 8% were found to have asymptomatic Grade 2 decrease in LVEF.

Embryo-Fetal Toxicity

ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. Verify the pregnancy status of females of reproductive potential prior to the initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for 7 months after the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose of ENHERTU.

Additional Dose Modifications

Thrombocytopenia

For Grade 3 thrombocytopenia (platelets <50 to 25 x 109/L) interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose. For Grade 4 thrombocytopenia (platelets <25 x 109/L) interrupt ENHERTU until resolved to Grade 1 or less, then reduce dose by one level.

Adverse Reactions

Metastatic Breast Cancer and HER2-Mutant NSCLC (5.4 mg/kg)

The pooled safety population reflects exposure to ENHERTU 5.4 mg/kg intravenously every 3 weeks in 984 patients in Study DS8201-A-J101 (NCT02564900), DESTINY-Breast01, DESTINY-Breast03, DESTINY-Breast04, and DESTINY-Lung02. Among these patients 65% were exposed for >6 months and 39% were exposed for >1 year. In this pooled safety population, the most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (76%), decreased white blood cell count (71%), decreased hemoglobin (66%), decreased neutrophil count (65%), decreased lymphocyte count (55%), fatigue (54%), decreased platelet count (47%), increased aspartate aminotransferase (48%), vomiting (44%), increased alanine aminotransferase (42%), alopecia (39%), increased blood alkaline phosphatase (39%), constipation (34%), musculoskeletal pain (32%), decreased appetite (32%), hypokalemia (28%), diarrhea (28%), and respiratory infection (24%).

HER2-Positive Metastatic Breast Cancer

DESTINY-Breast03

The safety of ENHERTU was evaluated in 257 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg intravenously every three weeks in DESTINY-Breast03. The median duration of treatment was 14 months (range: 0.7 to 30).

Serious adverse reactions occurred in 19% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were vomiting, interstitial lung disease, pneumonia, pyrexia, and urinary tract infection. Fatalities due to adverse reactions occurred in 0.8% of patients including COVID-19 and sudden death (one patient each).

ENHERTU was permanently discontinued in 14% of patients, of which ILD/pneumonitis accounted for 8%. Dose interruptions due to adverse reactions occurred in 44% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, leukopenia, anemia, thrombocytopenia, pneumonia, nausea, fatigue, and ILD/pneumonitis. Dose reductions occurred in 21% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were nausea, neutropenia, and fatigue.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (76%), decreased white blood cell count (74%), decreased neutrophil count (70%), increased aspartate aminotransferase (67%), decreased hemoglobin (64%), decreased lymphocyte count (55%), increased alanine aminotransferase (53%), decreased platelet count (52%), fatigue (49%), vomiting (49%), increased blood alkaline phosphatase (49%), alopecia (37%), hypokalemia (35%), constipation (34%), musculoskeletal pain (31%), diarrhea (29%), decreased appetite (29%), respiratory infection (22%), headache (22%), abdominal pain (21%), increased blood bilirubin (20%), and stomatitis (20%).

HER2-Low Metastatic Breast Cancer

DESTINY-Breast04

The safety of ENHERTU was evaluated in 371 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who received ENHERTU 5.4 mg/kg intravenously every 3 weeks in DESTINY-Breast04. The median duration of treatment was 8 months (range: 0.2 to 33) for patients who received ENHERTU.

Serious adverse reactions occurred in 28% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, pneumonia, dyspnea, musculoskeletal pain, sepsis, anemia, febrile neutropenia, hypercalcemia, nausea, pyrexia, and vomiting. Fatalities due to adverse reactions occurred in 4% of patients including ILD/pneumonitis (3 patients); sepsis (2 patients); and ischemic colitis, disseminated intravascular coagulation, dyspnea, febrile neutropenia, general physical health deterioration, pleural effusion, and respiratory failure (1 patient each).

ENHERTU was permanently discontinued in 16% of patients, of which ILD/pneumonitis accounted for 8%. Dose interruptions due to adverse reactions occurred in 39% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, fatigue, anemia, leukopenia, COVID-19, ILD/pneumonitis, increased transaminases, and hyperbilirubinemia. Dose reductions occurred in 23% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, thrombocytopenia, and neutropenia.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (76%), decreased white blood cell count (70%), decreased hemoglobin (64%), decreased neutrophil count (64%), decreased lymphocyte count (55%), fatigue (54%), decreased platelet count (44%), alopecia (40%), vomiting (40%), increased aspartate aminotransferase (38%), increased alanine aminotransferase (36%), constipation (34%), increased blood alkaline phosphatase (34%), decreased appetite (32%), musculoskeletal pain (32%), diarrhea (27%), and hypokalemia (25%).

Unresectable or Metastatic HER2-Mutant NSCLC (5.4 mg/kg)

DESTINY-Lung02 evaluated two dose levels (5.4 mg/kg [n=101] and 6.4 mg/kg [n=50]); however, only the results for the recommended dose of 5.4 mg/kg intravenously every 3 weeks are described below due to increased toxicity observed with the higher dose in patients with NSCLC, including ILD/pneumonitis.

The safety of ENHERTU was evaluated in 101 patients with unresectable or metastatic HER2-mutant NSCLC who received ENHERTU 5.4 mg/kg intravenously every three weeks in DESTINY‑Lung02. Nineteen percent of patients were exposed for >6 months.

Serious adverse reactions occurred in 30% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were ILD/pneumonitis, thrombocytopenia, dyspnea, nausea, pleural effusion, and increased troponin I. Fatality occurred in 1 patient with suspected ILD/pneumonitis (1%).

ENHERTU was permanently discontinued in 8% of patients. Adverse reactions which resulted in permanent discontinuation of ENHERTU were ILD/pneumonitis, diarrhea, hypokalemia, hypomagnesemia, myocarditis, and vomiting. Dose interruptions of ENHERTU due to adverse reactions occurred in 23% of patients. Adverse reactions which required dose interruption (>2%) included neutropenia and ILD/pneumonitis. Dose reductions due to an adverse reaction occurred in 11% of patients.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were nausea (61%), decreased white blood cell count (60%), decreased hemoglobin (58%), decreased neutrophil count (52%), decreased lymphocyte count (43%), decreased platelet count (40%), decreased albumin (39%), increased aspartate aminotransferase (35%), increased alanine aminotransferase (34%), fatigue (32%), constipation (31%), decreased appetite (30%), vomiting (26%), increased alkaline phosphatase (22%), and alopecia (21%).

Locally Advanced or Metastatic Gastric Cancer (6.4 mg/kg)

The safety of ENHERTU was evaluated in 187 patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma in DESTINY-Gastric01. Patients intravenously received at least one dose of either ENHERTU (N=125) 6.4 mg/kg every 3 weeks or either irinotecan (N=55) 150 mg/m2 biweekly or paclitaxel (N=7) 80 mg/m2 weekly for 3 weeks. The median duration of treatment was 4.6 months (range: 0.7 to 22.3) for patients who received ENHERTU.

Serious adverse reactions occurred in 44% of patients receiving ENHERTU 6.4 mg/kg. Serious adverse reactions in >2% of patients who received ENHERTU were decreased appetite, ILD, anemia, dehydration, pneumonia, cholestatic jaundice, pyrexia, and tumor hemorrhage. Fatalities due to adverse reactions occurred in 2.4% of patients: disseminated intravascular coagulation, large intestine perforation, and pneumonia occurred in one patient each (0.8%).

ENHERTU was permanently discontinued in 15% of patients, of which ILD accounted for 6%. Dose interruptions due to adverse reactions occurred in 62% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, anemia, decreased appetite, leukopenia, fatigue, thrombocytopenia, ILD, pneumonia, lymphopenia, upper respiratory tract infection, diarrhea, and hypokalemia. Dose reductions occurred in 32% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were neutropenia, decreased appetite, fatigue, nausea, and febrile neutropenia.

The most common (≥20%) adverse reactions, including laboratory abnormalities, were decreased hemoglobin (75%), decreased white blood cell count (74%), decreased neutrophil count (72%), decreased lymphocyte count (70%), decreased platelet count (68%), nausea (63%), decreased appetite (60%), increased aspartate aminotransferase (58%), fatigue (55%), increased blood alkaline phosphatase (54%), increased alanine aminotransferase (47%), diarrhea (32%), hypokalemia (30%), vomiting (26%), constipation (24%), increased blood bilirubin (24%), pyrexia (24%), and alopecia (22%).

Use in Specific Populations

  • Pregnancy: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months after the last dose of ENHERTU.
  • Lactation: There are no data regarding the presence of ENHERTU in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ENHERTU and for 7 months after the last dose.
  • Females and Males of Reproductive Potential:Pregnancy testing: Verify pregnancy status of females of reproductive potential prior to initiation of ENHERTU. Contraception: Females: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with ENHERTU and for 7 months after the last dose. Males: Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for 4 months after the last dose. Infertility: ENHERTU may impair male reproductive function and fertility.
  • Pediatric Use: Safety and effectiveness of ENHERTU have not been established in pediatric patients.
  • Geriatric Use: Of the 883 patients with breast cancer treated with ENHERTU 5.4 mg/kg, 22% were ≥65 years and 3.6% were ≥75 years. No overall differences in efficacy within clinical studies were observed between patients ≥65 years of age compared to younger patients. There was a higher incidence of Grade 3-4 adverse reactions observed in patients aged ≥65 years (60%) as compared to younger patients (48%). Of the 101 patients with unresectable or metastatic HER2-mutant NSCLC treated with ENHERTU 5.4 mg/kg, 40% were ≥65 years and 8% were ≥75 years. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients. Of the 125 patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma treated with ENHERTU 6.4 mg/kg in DESTINY-Gastric01, 56% were ≥65 years and 14% were ≥75 years. No overall differences in efficacy or safety were observed between patients ≥65 years of age compared to younger patients.
  • Renal Impairment: A higher incidence of Grade 1 and 2 ILD/pneumonitis has been observed in patients with moderate renal impairment. Monitor patients with moderate renal impairment more frequently. The recommended dosage of ENHERTU has not been established for patients with severe renal impairment (CLcr <30 mL/min).
  • Hepatic Impairment: In patients with moderate hepatic impairment, due to potentially increased exposure, closely monitor for increased toxicities related to the topoisomerase inhibitor. The recommended dosage of ENHERTU has not been established for patients with severe hepatic impairment (total bilirubin >3 times ULN and any AST).

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch.

Please see accompanying full Prescribing Information, including Boxed WARNINGS, and Medication Guide.

Notes

HER2 expression in solid tumors

HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of various tissue cells throughout the body and is involved in normal cell growth.1,2 In some cancers, HER2 expression is amplified or the cells have activating mutations.1,3 HER2 protein overexpression may occur as a result of HER2 gene amplification and is often associated with aggressive disease and poor prognosis.4

While HER2-directed therapies have been used to treat breast, gastric, lung and colorectal cancers, more research is needed evaluating their potential role in treating other HER2-expressing tumor types.2,5,6

HER2 is an emerging biomarker in biliary tract, bladder, cervical, endometrial, ovarian and pancreatic cancers.3 Testing is not routinely performed in these additional tumor types and as a result, available literature is limited. HER2 overexpression (IHC3+) has been observed at rates from 1% to 28% in these solid tumors.7,8 There is an unmet need for effective therapies for certain HER2-expressing solid tumors, particularly for those who have progressed on or are refractory to standard of care therapies as there are currently no approved HER2-directed therapies for these cancers.2,9

DESTINY-PanTumor02

DESTINY-PanTumor02 is a global, multicenter, multi-cohort, open-label Phase II trial evaluating the efficacy and safety of ENHERTU(5.4mg/kg) for the treatment of previously treated HER2-expressing tumors, including biliary tract cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer and other tumors.

The primary efficacy endpoint of DESTINY-PanTumor02 is confirmed ORR as assessed by investigator. Secondary endpoints include DoR, disease control rate, PFS, OS, safety, tolerability and pharmacokinetics.

DESTINY-PanTumor02 has enrolled 267 patients at multiple sites in Asia, Europe and North America. For more information about the trial, visit ClinicalTrials.gov.

ENHERTU

ENHERTU is a HER2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, ENHERTU is the lead ADC in the oncology portfolio of Daiichi Sankyo and the most advanced program in AstraZeneca’s ADC scientific platform. ENHERTUconsists of a HER2 monoclonal antibody attached to a topoisomerase I inhibitor payload, an exatecan derivative, via a stable tetrapeptide-based cleavable linker.

ENHERTU (5.4mg/kg) is approved in more than 50 countries for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a (or one or more) prior anti-HER2-based regimen, either in the metastatic setting or in the neoadjuvant or adjuvant setting, and have developed disease recurrence during or within six months of completing therapy based on the results from the DESTINY-Breast03 trial.

ENHERTU (5.4mg/kg) is approved in more than 40 countries for the treatment of adult patients with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in-situ hybridization [ISH]-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy based on the results from the DESTINY-Breast04 trial.

ENHERTU (5.4mg/kg) is approved in Israel and under accelerated approval in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer whose tumors have activating HER2 (ERBB2) mutations, as detected by a locally or regionally approved test, and who have received a prior systemic therapy based on the results from the DESTINY-Lung02 trial. Continued approval for this indication in the US may be contingent upon verification and description of clinical benefit in a confirmatory trial.

ENHERTU (6.4mg/kg) is approved in more than 30 countries for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen based on the results from the DESTINY-Gastric01 trial and/or DESTINY-Gastric02 trial.

ENHERTUdevelopment program

A comprehensive global development program is underway evaluating the efficacy and safety of ENHERTUmonotherapy across multiple HER2-targetable cancers. Trials in combination with other anticancer treatments, such as immunotherapy, are also underway.

Daiichi Sankyo collaboration

Daiichi Sankyo Company, Limited (TSE: 4568) [referred to as Daiichi Sankyo] and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU (a HER2-directed ADC) in March 2019, and datopotamab deruxtecan (DS-1062; a TROP2-directed ADC) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for the manufacturing and supply of ENHERTU and datopotamab deruxtecan.

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company’s focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on Twitter @AstraZenecaUS.

References

  1. ASCO. Breast Cancer. Available at: https://www.cancer.net/sites/cancer.net/files/asco_answers_guide_breast.pdf. Accessed July 2023.

  2. Iqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014; 852748.

  3. Omar N, et al. HER2-an emerging biomarker in non-breast and non-gastric cancers. Pathogenesis. 2015;2(3):1-9.

  4. Pillai R, et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. Cancer. 2017;1;123(21): 4099-4105.

  5. National Cancer Institute. Enhertu Marks First Targeted Therapy for HER2-Mutant Lung Cancer. Available at: https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-lung-cancer-enhertu-her2. Accessed July 2023.

  6. Siena S, et al. Targeting the Human Epidermal Growth Factor Receptor 2 (HER2) Oncogene in Colorectal Cancer. Ann Oncol. 2018 May; 29(5):1108-1119.

  7. Yan M, et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015 Mar;34(1):157-64.

  8. Buza N et al. Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Modern Pathology. 2013 Dec;26(12):1605-12.

  9. Meric-Bernstam F, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019 Apr;20(4):518-530.

US-78341Last Updated 07/23

Media Inquiries

Brendan McEvoy +1 302 885 2677

Jillian Gonzales +1 302 885 2677

US Media Mailbox: [email protected]

KEYWORDS: United States North America Delaware

INDUSTRY KEYWORDS: Cardiology Biotechnology FDA Health General Health Pharmaceutical Oncology Other Science Research Science Clinical Trials

MEDIA:

Logo
Logo

Papa Johns Appoints John Miller to Board of Directors

Papa Johns Appoints John Miller to Board of Directors

Miller Brings 45 Years of Restaurant Operations and Management Experience

ATLANTA–(BUSINESS WIRE)–
Papa John’s International, Inc. (NASDAQ: PZZA) (“Papa Johns®”) today announced that John Miller, Former President and Chief Executive Officer and Director of Denny’s Corporation (NASDAQ: DENN) has been appointed to the Company’s Board of Directors as a new independent director.

“We are pleased to welcome John to the Papa Johns Board,” said Christopher L. Coleman, Chair of the Papa Johns Board of Directors. “He is an accomplished restaurant industry veteran with a track record of over 45 years in restaurant operations and executive management experience at leading industry brands. John’s fresh perspective on the board, combined with his franchise, brand and development skills and insights, will strengthen our ability to support the management team in driving future growth and value creation, further bolstering our leadership position in the pizza segment.”

John Miller served as President and Chief Executive Officer for Denny’s Corporation (NASDAQ: DENN), responsible for leading the strategic direction of the company, and spent more than 11 years with Denny’s before retiring in August 2022. Prior to joining Denny’s, Mr. Miller served as Chief Executive Officer of Taco Bueno Restaurants, Inc. (2005-2011) and also spent 17 years with Brinker International, where he held numerous management positions.

“Papa Johns is an iconic brand within the restaurant space that is leading the industry in innovation, and I am honored to join the Board at such an exciting time for the company,” said Mr. Miller. “I look forward to sharing my industry and operational experience with the Board and management team to help advance Papa Johns’ strategic initiatives and deliver long-term profitable growth for all stakeholders.”

Rob Lynch, President and CEO of Papa Johns added, “We are thrilled to welcome John Miller to our Board. His wealth of experience and perspectives in the restaurant industry, including as a two-time CEO, will bring valuable insight and meaningful impact to Papa Johns. We look forward to working with John.”

About John Miller

John Miller is the Former President and Chief Executive Officer of Denny’s Corporation (NASDAQ: DENN) and an accomplished restaurant industry veteran. He joined Denny’s in February 2011, bringing extensive restaurant operations and management experience to the national diner chain with 1,647 restaurants operating globally. During his tenure he delivered consistent growth across the business while also driving innovation of the brand and operations by investing in new technologies. He continues to serve on Denny’s Board of Directors.

Mr. Miller recently served as Vice-Chair of the Board of Trustees of Wilberforce University, a historically Black College renowned for its work in this regard. During his time in Spartanburg, he was actively involved with United Way of Piedmont; Habitat for Humanity; The Spartanburg Academic Movement, a cradle-to-career model for education; and the One Spartanburg initiative for Spartanburg, South Carolina, to become a model town for America to witness.

Prior to joining Denny’s, Mr. Miller served as Chief Executive Officer of Taco Bueno Restaurants, Inc. (2005-2011). He also spent 17 years with Brinker International, where he held numerous management positions, including President of Romano’s Macaroni Grill; President of Brinker’s Mexican Concepts, responsible for overseeing On The Border and Cozymel’s; and Vice President, Franchise, for the Chili’s brand. Earlier in his career, he held various operations and restaurant management positions at Unigate Restaurant/Casa Bonita in Dallas, Texas.

John Miller’s achievements include the TDn2k Best People Practices Award, the IFMA Silver and Gold Plate Awards, the MUFSO Golden Chain Award, the Urban League of the Upstate’s Whitney M. Young, Jr. Humanitarian Award, The Spartanburg Area Chamber of Commerce Chairman’s Award, and The Denny’s 2018 Franchisee Association Chairman’s Award.

About Papa Johns

Papa John’s International, Inc. (NASDAQ: PZZA) (“Papa Johns”) opened its doors in 1984 with one goal in mind: BETTER INGREDIENTS. BETTER PIZZA. Papa Johns believes that using high quality ingredients leads to superior quality pizzas. Its original dough is made of only six ingredients and is fresh, never frozen. Papa Johns tops its pizzas with real cheese made from mozzarella, pizza sauce made with vine-ripened tomatoes that go from vine to can in the same day and meat free of fillers. It was the first national pizza delivery chain to announce the removal of artificial flavors and synthetic colors from its entire food menu. Papa Johns is co-headquartered in Atlanta, Ga. and Louisville, Ky. and is the world’s third-largest pizza delivery company with more than 5,700 restaurants in approximately 50 countries and territories. For more information about the Company or to order pizza online, visit www.papajohns.com or download the Papa Johns mobile app for iOS or Android.

Forward Looking Statements

Certain matters discussed in this press release which are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see “Part I. Item 1A. – Risk Factors” of the Annual Report on Form 10-K for the fiscal year ended December 25, 2022. We undertake no obligation to update publicly any forward-looking statements, whether as a result of future events, new information or otherwise.

Media Contact

Harrison Sheffield

Sr. Communications Manager

Papa John’s International

[email protected]

(470) 751-4483

Investor Relations Contact

Stacy Frole

Vice President Investor Relations

Papa John’s International

[email protected]

(470) 751-4513

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Retail Online Retail Restaurant/Bar Food/Beverage

MEDIA:

Logo
Logo

DoubleVerify Expands Media Quality Authentication to YouTube Shorts & Other Formats

DoubleVerify Expands Media Quality Authentication to YouTube Shorts & Other Formats

Brands benefit from DV’s industry-leading viewability and fraud measurement across YouTube Shorts, Masthead and In-feed Video Formats

NEW YORK–(BUSINESS WIRE)–DoubleVerify (“DV”) (NYSE: DV), a leading software platform for digital media measurement, data and analytics, announced an expansion of its quality solutions with Google’s Ads Data Hub for Measurement Partners, enabling media measurement and helping maximize advertiser performance on YouTube Shorts, Masthead and In-feed Video formats. The release leverages DV’s technology to help advertisers on YouTube Shorts ensure their video ads are viewable, by a human being and are safe from Fraud/Invalid Traffic (“IVT”).

YouTube launched Shorts as a new way for people and businesses to create entertaining, short-form videos using only their mobile phones. Shorts ads provide brands with an immersive, built-for-mobile opportunity to reach high-intent audiences against content aligned with their interests.

“We are excited to expand our solution to include viewability and fraud coverage on YouTube Shorts – giving global brands greater clarity and confidence in their investments,” said Mark Zagorski, CEO, DoubleVerify. “Short-form videos offer advertisers a high-engagement forum to connect with passionate online communities. This release enables our customers to authenticate their media and maximize campaign effectiveness.”

With DV’s quality verification technology, advertisers on Shorts benefit from:

  • Fraud Measurement: For advertising to perform, it must be seen by a real human being. DV identifies and protects advertisers against fraud and IVT – from compromised devices to bot manipulation.
  • Viewability Authentication: DV provides comprehensive viewability measurement, offering clarity into whether an ad has the opportunity to be seen and confirming its potential to make an impact.

In addition, DV also provides viewability and fraud measurement across YouTube Masthead and In-feed Video inventory. Advertisers have access to measurement data and insights across all new inventory through DV Pinnacle, the company’s unified service and analytics reporting platform, to monitor and optimize the performance of their YouTube ads campaigns.

DV has provided viewability and fraud measurement across YouTube and Google ad serving solutions since 2011. In 2018, DoubleVerify became a Google measurement partner for Brand Safety and Viewability. In 2020, DV launched Authentic Brand Suitability on Google Display & Video 360 and, in 2022, DV was the first verification provider to earn MRC accreditation for Independent Third-Party Viewability Reporting on YouTube. Earlier this year, DV launched DV Campaign Automator™ To Streamline The Entire Trafficking Workflow in Google Campaign Manager 360.

For more information about DoubleVerify, visit http://www.doubleverify.com.

About DoubleVerify

DoubleVerify (“DV”) (NYSE: DV) is a leading software platform for digital media measurement and analytics. Our mission is to make the digital advertising ecosystem stronger, safer and more secure, thereby preserving the fair value exchange between buyers and sellers of digital media. Hundreds of Fortune 500 advertisers employ our unbiased data and analytics to drive campaign quality and effectiveness, and to maximize return on their digital advertising investments – globally. Learn more at www.doubleverify.com.

Media:

Chris Harihar

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Professional Services Data Management Data Analytics Technology Audio/Video Mobile/Wireless Software

MEDIA:

First BanCorp. Announces Earnings for the Quarter Ended June 30, 2023

First BanCorp. Announces Earnings for the Quarter Ended June 30, 2023

  • Net income of $70.7 million, or $0.39 per diluted share, for the second quarter of 2023, consistent with the first quarter of 2023. Return on average assets for the second quarter of 2023 at 1.51%, compared to 1.55% for the first quarter of 2023.

  • Income before income taxes of $101.0 million for the second quarter of 2023, compared to $102.6 million for the first quarter of 2023.

  • On a non-GAAP basis, adjusted pre-tax, pre-provision income of $118.0 million for the second quarter of 2023, relatively flat compared to $118.1 million for the first quarter of 2023.

  • Net interest income of $199.8 million for the second quarter of 2023, compared to $200.9 million for the first quarter of 2023, while the net interest margin decreased to 4.23% for the second quarter of 2023 from 4.34% for the first quarter of 2023. The decrease in net interest income and margin primarily reflects higher interest expense on deposits that exceeded the benefit of higher loan yields and portfolio growth.

  • Provision for credit losses increased to $22.2 million for the second quarter of 2023, compared to $15.5 million for the first quarter of 2023, mainly due to a deterioration in the forecasted commercial real estate price index (“CRE price index”), as well as the growth in the consumer and the commercial and construction loan portfolios. The ratio of the ACL for loans and finance leases to total loans held for investment was 2.28% as of June 30, 2023, compared to 2.29% as of March 31, 2023.

  • Non-interest income increased to $36.3 million for the second quarter of 2023, compared to $32.5 million for the first quarter of 2023, mainly driven by a $3.6 million gain recognized from a legal settlement and a $1.6 million gain on the repurchase of $21.4 million in junior subordinated debentures, partially offset by $2.3 million in seasonal contingent insurance commissions recorded in the first quarter of 2023.

  • Non-interest expenses decreased by $2.4 million to $112.9 million for the second quarter of 2023, compared to $115.3 million for the first quarter of 2023, mainly driven by lower payroll taxes and bonuses as a result of employees reaching maximum taxable amounts. The efficiency ratio for the second quarter of 2023 was 47.83%, compared to 49.39% for the first quarter of 2023. On a non-GAAP basis, excluding the aforementioned gains, the efficiency ratio for the second quarter of 2023 was 48.91%.

  • Income tax expense decreased to $30.3 million for the second quarter of 2023, compared to $31.9 million for the first quarter of 2023, mainly related to lower pre-tax income and a lower estimated effective tax rate when compared to the prior quarter.

  • Credit quality variances:

    • Non-performing assets decreased by $7.9 million to $121.1 million as of June 30, 2023, driven by a $6.2 million charge-off recorded on a commercial and industrial participated loan in the Florida region in the power generation industry and a $3.1 million decrease in nonaccrual residential mortgage loans mainly due to loans restored to accrual status.

    • Annualized net charge-offs to average loans ratio increased to 0.67% for the second quarter of 2023, compared to 0.46% for the first quarter of 2023, mainly driven by the aforementioned charge-off recorded in the second quarter of 2023.

  • Total loans increased by $140.4 million from the prior quarter to $11.7 billion as of June 30, 2023. On a portfolio basis, the total loan growth consisted of increases of $88.2 million in consumer loans, primarily auto loans and leases, and $70.8 million in commercial and construction loans, partially offset by a decrease of $18.6 million in residential mortgage loans. In terms of geography, the total loan growth consisted of increases of $79.3 million in the Puerto Rico region, $42.5 million in the Virgin Islands region, and $18.6 million in the Florida region.

  • Total loan originations, including refinancings, renewals, and draws from existing commitments (other than credit card utilization activity), amounted to $1.1 billion in the second quarter of 2023, an increase of $8.9 million compared to the first quarter of 2023. The growth in total loan originations consisted of increases of $37.9 million in residential mortgage loan originations and $11.1 million in consumer loan originations, partially offset by a $40.1 million decrease in commercial and construction loan originations.

  • Total deposits increased by $767.7 million to $16.8 billion. Excluding brokered certificates of deposit (“brokered CDs”) and government deposits, total deposits decreased by $104.3 million to $13.0 billion as of June 30, 2023, consisting of reductions of $77.3 million in the Puerto Rico region, $22.5 million in the Florida region, and $4.5 million in the Virgin Islands region. The decrease in total deposits, excluding brokered CDs and government deposits, is net of a $149.4 million increase in time deposits.

  • Government deposits, which are fully collateralized, increased in the second quarter of 2023 by $761.3 million and totaled $3.4 billion as of June 30, 2023. The increase in government deposits reflected growth of $698.0 million in the Puerto Rico region, $62.5 million in the Virgin Islands region, and $0.8 million in the Florida region.

  • Brokered CDs increased by $110.7 million during the second quarter of 2023 to $363.6 million as of June 30, 2023, or 2.2% of total deposits.

  • Borrowings decreased by $546.1 million during the second quarter of 2023 to $0.7 billion as of June 30, 2023, driven by repayments of $425.0 million in short-term Federal Home Loan Bank (“FHLB”) advances, a $99.0 million decline in short-term securities sold under agreements to repurchase (“repurchase agreements”), and the repurchase of $21.4 million in junior subordinated debentures.

  • Cash and cash equivalents increased by $223.9 million to $1.0 billion as of June 30, 2023 even after the $546.1 million decrease in borrowings. When adding $2.2 billion of free high-quality liquid securities that could be liquidated or pledged within one day, total core liquidity amounted to $3.2 billion as of June 30, 2023, or 16.70% of total assets, compared to 16.77% as of March 31, 2023. Including the $980.9 million in available lending capacity at the FHLB, available liquidity increased to 21.82% of total assets as of June 30, 2023, compared to 21.42% as of March 31, 2023.

  • Capital ratios exceed required regulatory levels for bank holding companies and well-capitalized banks. The Corporation’s estimated total capital, common equity tier 1 (“CET1”) capital, tier 1 capital, and leverage ratios were 19.15%, 16.64%, 16.64%, and 10.73%, respectively, as of June 30, 2023. On a non-GAAP basis, the tangible common equity ratio was 7.03% as of June 30, 2023, compared to 7.12% as of March 31, 2023.

SAN JUAN, Puerto Rico–(BUSINESS WIRE)–
First BanCorp. (the “Corporation” or “First BanCorp.”) (NYSE: FBP), the bank holding company for FirstBank Puerto Rico (“FirstBank” or “the Bank”), today reported a net income of $70.7 million, or $0.39 per diluted share, for the second quarter of 2023, compared to $70.7 million, or $0.39 per diluted share, for the first quarter of 2023, and $74.7 million, or $0.38 per diluted share, for the second quarter of 2022.

Aurelio Alemán, President and Chief Executive Officer of First BanCorp., commented: “We continue to focus on our strategic imperatives as we deliver another strong quarter of profitable growth for the franchise. We generated $70.7 million in net income, or $0.39 per share, which translated into a strong Return on Average Assets of 1.51% for the quarter. Our well diversified loan portfolio expanded for the sixth consecutive quarter, credit quality metrics remained stable, and our enduring expense management discipline is evidenced by an industry-low efficiency ratio of approximately 47.83%. Our organization is well positioned to continue gaining market share in the markets we serve by employing our long-standing client-centric omnichannel sales and service approach.

Loan origination activity during the quarter was positive and in-line with our expectations and forward guidance. Total loans increased by $140.4 million during the quarter driven by strong growth in commercial and consumer loans in Puerto Rico, particularly in the auto lending segment. Total core deposits, which exclude brokered and government deposits, decreased by $104.3 million or 0.8%. Deposit reductions continue to be driven by a combination of rate-sensitive customers looking for higher-yielding non-bank options and the gradual reduction of excess liquidity, particularly in our main market. In terms of the franchise, during the second quarter we expanded our small business digital lending offering to our other regional operations and relaunched our new corporate portal, www.1firstbank.com, which serves as an important tool for expanding our self-service distribution channels and enhancing the digital experience of our customers.

Despite higher rates and inflationary pressures, economic trends in our main market remain positive driven by the unprecedented inflow of federal funds that are expected to support economic activity over the next decade coupled with new investors coming into our market. Credit demand remains solid, labor market trends continue to improve, and strong consumer sentiment is evidenced by the rise in auto and retail sales. We are highly encouraged by the economic prospects in Puerto Rico and its potential for continued growth.

Finally, we resumed the previously authorized share buyback program in July 2023 and expect to complete the pending $75 million authorization during the third quarter. In addition, we completed our capital planning process during the second quarter, and we are very pleased to announce that our Board approved a new $225 million common share repurchase program that we expect to execute by the third quarter of 2024. Our ample capital position remains significantly above “well capitalized” thresholds which allows us to continue growing the franchise under any operating environment and supporting our people and the communities we serve while enhancing shareholder value.”

NON-GAAP DISCLOSURES

This press release contains GAAP financial measures and non-GAAP financial measures. Non-GAAP financial measures are used when management believes that the presentation of these non-GAAP financial measures enhances the ability of analysts and investors to analyze trends in the Corporation’s business and understand the performance of the Corporation. The Corporation may utilize these non-GAAP financial measures as guides in its budgeting and long-term planning process. Where non-GAAP financial measures are used, the most comparable GAAP financial measure, as well as the reconciliation of the non-GAAP financial measure to the most comparable GAAP financial measure, can be found in the text or in the tables in or attached to this press release. Any analysis of these non-GAAP financial measures should be used only in conjunction with results presented in accordance with GAAP.

Certain non-GAAP financial measures, such as adjusted net income, adjusted pre-tax, pre-provision income, adjusted non-interest income, and adjusted efficiency ratio, exclude the effect of items that management believes are not reflective of core operating performance (the “Special Items”). Other non-GAAP financial measures include adjusted net interest income and margin, tangible common equity, tangible book value per common share, and certain capital ratios. These measures should be read in conjunction with the accompanying tables (Exhibit A), which are an integral part of this press release, and the Corporation’s other financial information that is presented in accordance with GAAP.

Special Items

The financial results for the first quarter of 2023 and second quarter of 2022 did not include any significant Special Items. The financial results for the second quarter of 2023 included the following Special Items:

Quarter ended June 30, 2023

  • A $3.6 million ($2.3 million after-tax) gain recognized from a legal settlement reflected in the condensed consolidated statements of income as part of other non-interest income.

  • A $1.6 million gain on the repurchase of $21.4 million in junior subordinated debentures reflected in the condensed consolidated statements of income as “Gain on early extinguishment of debt.” The junior subordinated debentures are reflected in the condensed consolidated statements of financial condition as “Other borrowings.” The purchase price equated to 92.5% of the $21.4 million par value. The 7.5% discount resulted in the gain of $1.6 million. The gain, realized at the holding company level, had no effect on the income tax expense in the second quarter of 2023.

Non-GAAP Financial Measures

Adjusted Pre-Tax, Pre-Provision Income

Adjusted pre-tax, pre-provision income is a non-GAAP performance metric that management uses and believes that investors may find useful in analyzing underlying performance trends, particularly in times of economic stress, including as a result of natural catastrophes or health epidemics. Adjusted pre-tax, pre-provision income, as defined by management, represents income before income taxes adjusted to exclude the provisions for credit losses on loans, unfunded loan commitments and debt securities and any gains or losses on sales of investment securities. In addition, from time to time, earnings are also adjusted for certain items that management believes are not reflective of core operating performance regarded as Special Items.

Tangible Common Equity Ratio and Tangible Book Value per Common Share

The tangible common equity ratio and tangible book value per common share are non-GAAP financial measures that management believes are generally used by the financial community to evaluate capital adequacy. Tangible common equity is total common equity less goodwill and other intangibles. Tangible assets are total assets less goodwill and other intangibles. Management uses and believes that many stock analysts use the tangible common equity ratio and tangible book value per common share in conjunction with other more traditional bank capital ratios to compare the capital adequacy of banking organizations with significant amounts of goodwill or other intangible assets, typically stemming from the use of the purchase method of accounting for mergers and acquisitions. Accordingly, the Corporation believes that disclosure of these financial measures may be useful to investors. Neither tangible common equity nor tangible assets, or the related measures, should be considered in isolation or as a substitute for stockholders’ equity, total assets, or any other measure calculated in accordance with GAAP. Moreover, the manner in which the Corporation calculates its tangible common equity, tangible assets, and any other related measures may differ from that of other companies reporting measures with similar names.

Net Interest Income Excluding Valuations, and on a Tax-Equivalent Basis

Net interest income, interest rate spread, and net interest margin are reported excluding the changes in the fair value of derivative instruments and on a tax-equivalent basis in order to provide to investors additional information about the Corporation’s net interest income that management uses and believes should facilitate comparability and analysis of the periods presented. The changes in the fair value of derivative instruments have no effect on interest due or interest earned on interest-bearing liabilities or interest-earning assets, respectively. The tax-equivalent adjustment to net interest income recognizes the income tax savings when comparing taxable and tax-exempt assets and assumes a marginal income tax rate. Income from tax-exempt earning assets is increased by an amount equivalent to the taxes that would have been paid if this income had been taxable at statutory rates. Management believes that it is a standard practice in the banking industry to present net interest income, interest rate spread, and net interest margin on a fully tax-equivalent basis. This adjustment puts all earning assets, most notably tax-exempt securities and tax-exempt loans, on a common basis that management believes facilitates comparison of results to the results of peers.

NET INCOME AND RECONCILIATION TO ADJUSTED NET INCOME (NON-GAAP)

Net income was $70.7 million for the second quarter of 2023, or $0.39 per diluted share, consistent with the first quarter of 2023. The following table reconciles, for the second quarter of 2023 and six-month period ended June 30, 2023, the net income to adjusted net income and adjusted earnings per share, which are non-GAAP financial measures that exclude the significant Special Items identified above, and shows the net income and earnings per diluted share for the first quarter of 2023, the second quarter of 2022, and six-month period ended June 30, 2022.

 

Quarter Ended

 

Six Month-Period Ended

 

June 30, 2023

 

March 31, 2023

 

June 30, 2022

 

June 30, 2023

 

June 30, 2022

(In thousands, except per share information)

 

 

 

 

 

Net income, as reported (GAAP)

$

70,655

 

$

70,698

$

74,695

$

141,353

 

$

157,295

Adjustments:

 

 

 

 

 

Gain recognized from legal settlement

 

(3,600

)

 

 

 

(3,600

)

 

Gain on early extinguishment of debt

 

(1,605

)

 

 

 

(1,605

)

 

Income tax impact of adjustments

 

1,350

 

 

 

 

1,350

 

 

Adjusted net income attributable to common stockholders (non-GAAP)

$

66,800

 

$

70,698

$

74,695

$

137,498

 

$

157,295

Weighted-average diluted shares outstanding

 

179,277

 

 

181,236

 

195,366

 

180,253

 

 

197,441

Earnings Per Share – diluted (GAAP)

$

0.39

 

$

0.39

$

0.38

$

0.78

 

$

0.80

Adjusted Earnings Per Share – diluted (Non-GAAP)

$

0.37

 

$

0.39

$

0.38

$

0.76

 

$

0.80

 

 

 

 

 

 

INCOME BEFORE INCOME TAXES AND RECONCILIATION TO ADJUSTED PRE-TAX, PRE-PROVISION INCOME (NON-GAAP)

Income before income taxes was $101.0 million for the second quarter of 2023, compared to $102.6 million for the first quarter of 2023. For the six-month period ended June 30, 2023, income before income taxes was $203.6 million, compared to $234.4 million for the same period in 2022. Adjusted pre-tax, pre-provision income was $118.0 million for the second quarter of 2023, compared to $118.1 million for the first quarter of 2023. For the six-month period ended June 30, 2023, adjusted pre-tax, pre-provision income was $236.1 million, compared to $230.6 million for the same period in 2022. The following table reconciles income before income taxes to adjusted pre-tax, pre-provision income for the last five quarters and for the six-month periods ended June 30, 2023 and 2022:

 

 

Quarter Ended

Six-Month Period Ended

 

 

June 30, 2023

March 31, 2023

December 31, 2022

September 30, 2022

June 30, 2022

June 30, 2023

June 30, 2022

(Dollars in thousands)

 

 

 

 

 

 

 

 

Income before income taxes

 

$

100,939

 

$

102,633

 

$

106,530

 

$

106,631

 

$

108,798

 

$

203,572

 

$

234,423

 

Add/Less: Provision for credit losses expense (benefit)

 

 

22,230

 

 

15,502

 

 

15,712

 

 

15,783

 

 

10,003

 

 

37,732

 

 

(3,799

)

Less: Gain recognized from legal settlement

 

 

(3,600

)

 

 

 

 

 

 

 

 

 

(3,600

)

 

 

Less: Gain on early extinguishment of debt

 

 

(1,605

)

 

 

 

 

 

 

 

 

 

(1,605

)

 

 

Adjusted pre-tax, pre-provision income (1)

 

$

117,964

 

$

118,135

 

$

122,242

 

$

122,414

 

$

118,801

 

$

236,099

 

$

230,624

 

Change from most recent prior period (amount)

 

$

(171

)

$

(4,107

)

$

(172

)

$

3,613

 

$

6,978

 

$

5,475

 

$

47,581

 

Change from most recent prior period (percentage)

 

 

-0.1

%

 

-3.4

%

 

-0.1

%

 

3.0

%

 

6.2

%

 

2.4

%

 

26.0

%

(1)

Non-GAAP financial measure. See Non-GAAP Disclosures above for the definition and additional information about this non-GAAP financial measure.

NET INTEREST INCOME

The following table sets forth information concerning net interest income for the last five quarters:

 

 

Quarter Ended

(Dollars in thousands)

 

June 30,2023

 

March 31, 2023

 

December 31, 2022

 

September 30, 2022

 

June 30,2022

Net Interest Income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

$

252,204

 

$

242,396

 

$

233,452

 

$

222,683

 

$

208,625

Interest expense

 

 

52,389

 

 

41,511

 

 

27,879

 

 

14,773

 

 

12,439

Net interest income

 

$

199,815

 

$

200,885

 

$

205,573

 

$

207,910

 

$

196,186

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average Balances

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loans and leases

 

$

11,591,516

 

$

11,519,399

 

$

11,364,963

 

$

11,218,864

 

$

11,102,310

Total securities, other short-term investments and interest-bearing cash balances

 

 

7,333,989

 

 

7,232,347

 

 

7,314,293

 

 

7,938,530

 

 

8,568,022

Average interest-earning assets

 

$

18,925,505

 

$

18,751,746

 

$

18,679,256

 

$

19,157,394

 

$

19,670,332

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average interest-bearing liabilities

 

$

11,176,385

 

$

10,957,892

 

$

10,683,776

 

$

11,026,975

 

$

11,567,228

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average Yield/Rate

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average yield on interest-earning assets – GAAP

 

 

5.35%

 

 

5.24%

 

 

4.96%

 

 

4.61%

 

 

4.25%

Average rate on interest-bearing liabilities – GAAP

 

 

1.88%

 

 

1.54%

 

 

1.04%

 

 

0.53%

 

 

0.43%

Net interest spread – GAAP

 

 

3.47%

 

 

3.70%

 

 

3.92%

 

 

4.08%

 

 

3.82%

Net interest margin – GAAP

 

 

4.23%

 

 

4.34%

 

 

4.37%

 

 

4.31%

 

 

4.00%

Net interest income amounted to $199.8 million for the second quarter of 2023, a decrease of $1.1 million, compared to $200.9 million for the first quarter of 2023. The decrease in net interest income reflects the following:

  • An $11.7 million increase in interest expense on interest-bearing deposits, including:

    • A $4.9 million increase in interest expense on time deposits, excluding brokered CDs, mainly due to approximately $3.9 million associated with higher rates paid in the second quarter of 2023 on new issuances and renewals; the $169.1 million increase in the average balance that resulted in approximately $0.8 million of additional interest expense; and approximately a $0.2 million increase associated with an additional day in the second quarter of 2023. The average cost of non-brokered time deposits in the second quarter of 2023 increased 63 basis points to 2.50% when compared to the previous quarter.

    • A $4.7 million increase in interest expense on interest-bearing checking and saving accounts, of which approximately $4.3 million was driven by the increase in average rates paid in the second quarter of 2023, primarily in public funds accounts, and $0.2 million was related to an additional day in the second quarter of 2023. The average cost of interest-bearing checking and saving accounts increased by 24 basis points to 1.18% as compared to 0.94% in the previous quarter. Excluding public sector deposits, the average cost of interest-bearing checking and saving accounts for the second quarter of 2023 was 0.67%, as compared to 0.58% in the previous quarter.

    • A $2.1 million increase in interest expense on brokered CDs, mainly driven by an increase of $166.9 million in the average balance, which resulted in additional interest expense of approximately $1.8 million and, to a lesser extent, the effect of higher rates paid in the second quarter of 2023.

Partially offset by:

  • A $3.9 million increase in interest income on consumer loans and finance leases, of which approximately $1.6 million was related to an increase of $71.8 million in the average balance of this portfolio; $1.3 million was due to higher yields, mainly in the auto loans and finance leases portfolios; and $1.0 million was related to an additional day in the second quarter of 2023.

  • A $3.4 million increase in interest income on commercial and construction loans, of which approximately $1.9 million was mainly related to higher interest rates in the upward repricing of variable-rate loans and new loan originations, $1.0 million was related to an additional day in the second quarter of 2023, and approximately $0.6 million was related to the $27.1 million increase in the average balance of this portfolio.

  • A $2.4 million increase in interest income from interest-bearing cash balances and investment securities, mainly due to a $3.2 million increase in interest income from interest-bearing cash balances, primarily consisting of cash balances deposited at the Federal Reserve Bank (“FED”), mainly driven by the $213.1 million increase in the average balance; and a $0.4 million increase in dividends received from the FHLB. Partially offsetting these increases was a $1.1 million decrease in interest income on the debt securities portfolio, mainly due to higher U.S. agencies’ mortgage-backed securities (“MBS”) premium amortization expense associated with changes in anticipated prepayments, and the decrease of $107.5 million in the average balance.

  • A $0.8 million decrease in interest expense on borrowings, mainly driven by approximately $1.1 million associated with the $94.9 million decrease in the average balance of FHLB advances, driven by the precautionary liquidity measures taken at the end of the first quarter of 2023, partially offset by a higher average cost of funds in the second quarter.

  • A $0.1 million increase in interest income on residential mortgage loans.

Net interest margin for the second quarter of 2023 decreased to 4.23%, compared to 4.34% for the first quarter of 2023, mainly reflecting the effect of higher rates paid on deposits and an increasing migration from non-interest-bearing and other low cost deposits to higher cost time deposits that exceeded the increase in earning asset yields over the quarter.

NON-INTEREST INCOME

The following table sets forth information concerning non-interest income for the last five quarters:

 

Quarter Ended

 

June 30,2023

 

March 31, 2023

 

December 31, 2022

 

September 30, 2022

 

June 30,2022

(In thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Service charges and fees on deposit accounts

$

9,287

 

$

9,541

 

$

9,174

 

$

9,820

 

$

9,466

Mortgage banking activities

 

2,860

 

 

2,812

 

 

2,572

 

 

3,400

 

 

4,082

Insurance commission income

 

2,747

 

 

4,847

 

 

2,898

 

 

2,624

 

 

2,946

Card and processing income

 

11,135

 

 

10,918

 

 

10,601

 

 

9,834

 

 

10,300

Gain on early extinguishment of debt

 

1,605

 

 

 

 

 

 

 

 

Other non-interest income

 

8,637

 

 

4,400

 

 

4,355

 

 

4,015

 

 

4,147

Non-interest income

$

36,271

 

$

32,518

 

$

29,600

 

$

29,693

 

$

30,941

Non-interest income amounted to $36.3 million for the second quarter of 2023, compared to $32.5 million for the first quarter of 2023. Non-interest income for the second quarter of 2023 includes the $3.6 million gain recognized from a legal settlement included as part of other non-interest income and the $1.6 million gain on the repurchase of $21.4 million in junior subordinated debentures included as part of gain on early extinguishment of debt. On a non-GAAP basis, excluding the effect of these Special Items, adjusted non-interest income decreased by $1.4 million mainly due to:

  • A $2.1 million decrease in insurance commission income mainly driven by $2.3 million in seasonal contingent commissions recorded in the first quarter of 2023 based on the prior year’s production of insurance policies.

Partially offset by:

  • A $0.6 million increase in adjusted other non-interest income mainly driven by the effect during the second quarter of 2023 of $0.3 million in debit card incentives collected during the second quarter of 2023 and a $0.2 million gain recognized from the sale of a fixed asset in the Florida region.

NON-INTEREST EXPENSES

The following table sets forth information concerning non-interest expenses for the last five quarters:

 

Quarter Ended

 

June 30,2023

 

March 31, 2023

 

December 31, 2022

 

September 30, 2022

 

June 30,2022

(In thousands)

 

 

 

 

 

 

 

 

 

Employees’ compensation and benefits

$

54,314

 

 

$

56,422

 

 

$

52,241

 

 

$

52,939

 

 

$

51,304

 

Occupancy and equipment

 

21,097

 

 

 

21,186

 

 

 

21,843

 

 

 

22,543

 

 

 

21,505

 

Business promotion

 

4,167

 

 

 

3,975

 

 

 

5,590

 

 

 

5,136

 

 

 

4,042

 

Professional service fees:

 

 

 

 

 

 

 

 

 

Collections, appraisals and other credit-related fees

 

1,231

 

 

 

848

 

 

 

1,483

 

 

 

1,261

 

 

 

1,075

 

Outsourcing technology services

 

7,278

 

 

 

8,141

 

 

 

7,806

 

 

 

7,564

 

 

 

7,636

 

Other professional fees

 

3,087

 

 

 

2,984

 

 

 

3,380

 

 

 

3,724

 

 

 

3,325

 

Taxes, other than income taxes

 

5,124

 

 

 

5,112

 

 

 

5,211

 

 

 

5,349

 

 

 

4,689

 

FDIC deposit insurance

 

2,143

 

 

 

2,133

 

 

 

1,544

 

 

 

1,466

 

 

 

1,466

 

Other insurance and supervisory fees

 

2,352

 

 

 

2,368

 

 

 

2,429

 

 

 

2,387

 

 

 

2,303

 

Net gain on OREO operations

 

(1,984

)

 

 

(1,996

)

 

 

(2,557

)

 

 

(1,064

)

 

 

(1,485

)

Credit and debit card processing expenses

 

6,540

 

 

 

5,318

 

 

 

6,362

 

 

 

6,410

 

 

 

5,843

 

Communications

 

1,992

 

 

 

2,216

 

 

 

2,322

 

 

 

2,272

 

 

 

1,978

 

Other non-interest expenses

 

5,576

 

 

 

6,561

 

 

 

5,277

 

 

 

5,202

 

 

 

4,645

 

Total non-interest expenses

$

112,917

 

 

$

115,268

 

 

$

112,931

 

 

$

115,189

 

 

$

108,326

 

Non-interest expenses amounted to $112.9 million in the second quarter of 2023, a decrease of $2.4 million from $115.3 million in the first quarter of 2023. The $2.4 million decrease reflects the following significant variances:

  • A $2.1 million decrease in employees’ compensation and benefits expense, mainly driven by a decrease in bonuses and payroll taxes due to employees reaching maximum taxable amounts.

  • A $1.0 million decrease in other non-interest expenses, mainly due to reserve releases of legal and operational reserves recorded during the second quarter of 2023.

  • A $0.4 million decrease in professional service fees, mainly due to a $0.9 million decrease in outsourcing technology service fees, partially offset by a $0.4 million increase in collections, appraisals, and other credit-related fees.

  • A $0.2 million decrease in communication expenses.

Partially offset by:

  • A $1.2 million increase in credit and debit card processing expenses, mainly as a result of incentives received during the first quarter of 2023.

  • A $0.2 million increase in business promotion expenses, mainly as a result of higher advertising and sponsorship expenses incurred during the second quarter of 2023 associated with the commemoration of the 75th anniversary of the Bank and an increase in donations, partially offset by a $0.6 million decrease in credit card loyalty reward program expense associated with lower historical trends of customer redemptions.

INCOME TAXES

The Corporation recorded an income tax expense of $30.3 million for the second quarter of 2023, compared to $31.9 million for the first quarter of 2023. The decrease was mainly related to lower pre-tax income and a lower estimated effective tax rate when compared to the previous quarter.

The Corporation’s estimated effective tax rate, excluding entities with pre-tax losses from which a tax benefit cannot be recognized and discrete items, was 30.1% for the second quarter of 2023, compared to 31.2% for the first quarter of 2023. As of June 30, 2023, the Corporation had a deferred tax asset of $153.9 million, net of a valuation allowance of $184.2 million against the deferred tax assets.

CREDIT QUALITY

Non-Performing Assets

The following table sets forth information concerning non-performing assets for the last five quarters:

(Dollars in thousands)

June 30, 2023

March 31, 2023

December 31, 2022

September 30, 2022

June 30,2022

Nonaccrual loans held for investment:

 

 

 

 

 

Residential mortgage

$

33,252

 

$

36,410

 

$

42,772

 

$

43,036

 

$

44,588

 

Commercial mortgage

 

21,536

 

 

21,598

 

 

22,319

 

 

23,741

 

 

24,753

 

Commercial and Industrial

 

9,194

 

 

13,404

 

 

7,830

 

 

15,715

 

 

17,079

 

Construction

 

1,677

 

 

1,794

 

 

2,208

 

 

2,237

 

 

2,375

 

Consumer and finance leases

 

16,362

 

 

15,936

 

 

14,806

 

 

12,787

 

 

10,315

 

Total nonaccrual loans held for investment

$

82,021

 

$

89,142

 

$

89,935

 

$

97,516

 

$

99,110

 

OREO

 

31,571

 

 

32,862

 

 

31,641

 

 

38,682

 

 

41,706

 

Other repossessed property

 

5,404

 

 

4,743

 

 

5,380

 

 

4,936

 

 

3,840

 

Other assets (1)

 

2,111

 

 

2,203

 

 

2,202

 

 

2,193

 

 

2,809

 

Total non-performing assets (2)

$

121,107

 

$

128,950

 

$

129,158

 

$

143,327

 

$

147,465

 

 

 

 

 

 

 

Past due loans 90 days and still accruing (3)

$

63,211

 

$

74,380

 

$

80,517

 

$

81,790

 

$

94,485

 

Nonaccrual loans held for investment to total loans held for investment

 

0.70

%

 

0.77

%

 

0.78

%

 

0.86

%

 

0.88

%

Nonaccrual loans to total loans

 

0.70

%

 

0.77

%

 

0.78

%

 

0.86

%

 

0.88

%

Non-performing assets to total assets

 

0.63

%

 

0.68

%

 

0.69

%

 

0.78

%

 

0.76

%

(1)

Residential pass-through MBS issued by the Puerto Rico Housing Finance Authority (“PRHFA”) held as part of the available-for-sale debt securities portfolio.

(2)

Excludes purchased-credit deteriorated (“PCD”) loans previously accounted for under Accounting Standards Codification (“ASC”) Subtopic 310-30 for which the Corporation made the accounting policy election of maintaining pools of loans as “units of account” both at the time of adoption of current expected credit losses (“CECL”) on January 1, 2020 and on an ongoing basis for credit loss measurement. These loans will continue to be excluded from nonaccrual loan statistics as long as the Corporation can reasonably estimate the timing and amount of cash flows expected to be collected on the loan pools. The portion of such loans contractually past due 90 days or more amounted to $9.5 million as of June 30, 2023 (March 31, 2023 – $10.4 million; December 31, 2022 – $12.0 million; September 30, 2022 – $12.8 million; June 30, 2022 – $15.3 million).

(3)

These include rebooked loans, which were previously pooled into Government National Mortgage Association (“GNMA”) securities, amounting to $6.5 million as of June 30, 2023 (March 31, 2023 – $7.1 million; December 31, 2022 – $10.3 million; September 30, 2022 – $8.0 million; June 30, 2022 – $10.8 million). Under the GNMA program, the Corporation has the option but not the obligation to repurchase loans that meet GNMA’s specified delinquency criteria. For accounting purposes, the loans subject to the repurchase option are required to be reflected on the financial statements with an offsetting liability.

Variances in credit quality metrics:

  • Total non-performing assets decreased by $7.9 million to $121.1 million as of June 30, 2023, compared to $129.0 million as of March 31, 2023. Total nonaccrual loans held for investment decreased by $7.1 million to $82.0 million as of June 30, 2023, compared to $89.1 million as of March 31, 2023.

    The decrease in non-performing assets was mainly driven by:

    • A $4.4 million decrease in nonaccrual commercial and construction loans, mainly related to the aforementioned $6.2 million charge-off recorded during the second quarter of 2023, partially offset by the inflow of a $1.5 million commercial and industrial loan in the Puerto Rico region.

    • A $3.1 million decrease in nonaccrual residential mortgage loans, mainly related to $2.7 million of loans restored to accrual status.

    • A $1.3 million decrease in the other real estate owned (“OREO”) portfolio balance, mainly attributable to the sale of residential properties in the Puerto Rico region.

      Partially offset by:

    • A $0.7 million increase in other repossessed property, mainly consisting of repossessed automobiles.

    • A $0.4 million increase in nonaccrual consumer loans, mainly auto loans and finance leases.
  • Inflows to nonaccrual loans held for investment were $24.9 million in the second quarter of 2023, a decrease of $4.8 million compared to inflows of $29.7 million in the first quarter of 2023. Inflows to nonaccrual commercial and construction loans were $3.1 million in the second quarter of 2023, a decrease of $5.0 million compared to inflows of $8.1 million in the first quarter of 2023 mainly due to the inflow of a $7.1 million commercial and industrial participated loan in the Florida region during the first quarter of 2023. Inflows to nonaccrual consumer loans were $18.8 million, a decrease of $0.7 million compared to inflows of $19.5 million in the first quarter of 2023. Inflows to nonaccrual residential mortgage loans were $3.0 million in the second quarter of 2023, an increase of $0.9 million compared to inflows of $2.1 million in the first quarter of 2023. See Early Delinquency below for additional information.

  • Adversely classified commercial and construction loans decreased by $4.3 million to $65.7 million as of June 30, 2023, mainly driven by the aforementioned $6.2 million charge-off recorded in the second quarter of 2023.

Early Delinquency

Total loans held for investment in early delinquency (i.e., 30-89 days past due accruing loans, as defined in regulatory reporting instructions) amounted to $118.5 million as of June 30, 2023, an increase of $24.0 million, compared to $94.5 million as of March 31, 2023. The variances by major portfolio categories are as follows:

  • Consumer loans in early delinquency increased in the second quarter of 2023 by $12.0 million to $78.4 million, mainly in the auto loan portfolio.

  • Commercial and construction loans in early delinquency increased by $6.3 million to $9.2 million, mainly due to a $4.5 million commercial mortgage loan in the Puerto Rico region that matured and is in the process of renewal but for which the Corporation continues to receive interest and principal payments from the borrower.

  • Residential mortgage loans in early delinquency increased by $5.7 million to $30.9 million.

Allowance for Credit Losses

The following table summarizes the activity of the allowance for credit losses (“ACL”) for on-balance sheet and off-balance sheet exposures during the second and first quarters of 2023:

 

 

Quarter ended June 30, 2023

 

 

Loans and Finance Leases

 

 

 

Debt Securities

 

 

Residential

Mortgage

 

Commercial

and

Construction

 

Consumer

Loans and

Finance

 

Total Loans

and Finance

 

Unfunded

Loans

 

Held-to

 

Available-

 

 

Allowance for Credit Losses

 

Loans

 

Loans

 

Leases

 

Leases

 

Commitments

 

Maturity

 

for-Sale

 

Total ACL

(Dollars in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance for credit losses, beginning balance

 

$

64,403

 

 

$

70,926

 

 

$

130,238

 

 

$

265,567

 

 

$

4,168

 

 

$

7,646

 

 

$

449

 

 

$

277,830

 

Provision for credit losses – (benefit) expense

 

 

(3,500

)

 

 

10,198

 

 

 

14,072

 

 

 

20,770

 

 

 

721

 

 

 

755

 

 

 

(16

)

 

 

22,230

 

Net charge-offs

 

 

(389

)

 

 

(5,879

)

 

 

(13,011

)

 

 

(19,279

)

 

 

 

 

 

 

 

 

 

 

 

(19,279

)

Allowance for credit losses, end of period

 

$

60,514

 

 

$

75,245

 

 

$

131,299

 

 

$

267,058

 

 

$

4,889

 

 

$

8,401

 

 

$

433

 

 

$

280,781

 

Amortized cost of loans and finance leases

 

$

2,793,790

 

 

$

5,430,268

 

 

$

3,495,257

 

 

$

11,719,315

 

 

 

 

 

 

 

 

 

Allowance for credit losses on loans to amortized cost

 

 

2.17

%

 

 

1.39

%

 

 

3.76

%

 

 

2.28

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Quarter ended March 31, 2023

 

 

Loans and Finance Leases

 

 

 

Debt Securities

 

 

Residential

Mortgage

 

Commercial

and

Construction

 

Consumer

Loans and

Finance

 

Total Loans

and Finance

 

Unfunded

Loans

 

Held-to

 

Available-

 

 

Allowance for Credit Losses

 

Loans

 

Loans

 

Leases

 

Leases

 

Commitments

 

-Maturity

 

for-Sale

 

Total ACL

(Dollars in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance for credit losses, beginning balance

 

$

62,760

 

 

$

70,278

 

 

$

127,426

 

 

$

260,464

 

 

$

4,273

 

 

$

8,286

 

 

$

458

 

 

$

273,481

 

Impact of adoption of ASU 2022-02 (1)

 

 

2,056

 

 

 

7

 

 

 

53

 

 

 

2,116

 

 

 

 

 

 

 

 

 

 

 

 

2,116

 

Provision for credit losses – expense (benefit)

 

 

73

 

 

 

456

 

 

 

15,727

 

 

 

16,256

 

 

 

(105

)

 

 

(640

)

 

 

(9

)

 

 

15,502

 

Net (charge-offs) recoveries

 

 

(486

)

 

 

185

 

 

 

(12,968

)

 

 

(13,269

)

 

 

 

 

 

 

 

 

 

 

 

(13,269

)

Allowance for credit losses, end of period

 

$

64,403

 

 

$

70,926

 

 

$

130,238

 

 

$

265,567

 

 

$

4,168

 

 

$

7,646

 

 

$

449

 

 

$

277,830

 

Amortized cost of loans and finance leases

 

$

2,811,528

 

 

$

5,359,512

 

 

$

3,406,945

 

 

$

11,577,985

 

 

 

 

 

 

 

 

 

Allowance for credit losses on loans to amortized cost

 

 

2.29

%

 

 

1.32

%

 

 

3.82

%

 

 

2.29

%

 

 

 

 

 

 

 

 

 

(1)

Related to the adoption on January 1, 2023 of Accounting Standards Update (“ASU”) 2022-02, “Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures,” for which the Corporation elected to discontinue the use of a discounted cash flow methodology for restructured accruing loans.

The main variances of the total ACL by main categories are discussed below:

Allowance for Credit Losses for Loans and Finance Leases

As of June 30, 2023, the ACL for loans and finance leases was $267.1 million, an increase of $1.5 million, from $265.6 million as of March 31, 2023. The ACL for commercial and construction loans increased by $4.3 million, mainly due to a deterioration in the forecasted CRE Price Index to account for an increased uncertainty in the CRE market at a national level that could potentially impact the markets we serve coupled with the growth in the commercial and construction loan portfolios, partially offset by the aforementioned charge-off recorded during the second quarter of 2023. The ACL for consumer loans increased by $1.1 million, primarily reflecting the effect of the increase in the size of the consumer loan portfolios, partially offset by updated macroeconomic variables, such as the unemployment rate, which are now forecasted to deteriorate at a slower pace than previously expected. The ACL for residential mortgage loans decreased by $3.9 million, mainly due to a more favorable economic outlook in the projection of certain forecasted macroeconomic variables, such as the Regional Home Price Index.

  • The provision for credit losses on loans and finance leases was $20.8 million for the second quarter of 2023, compared to $16.3 million in the first quarter of 2023.

    • Provision for credit losses for the commercial and construction loan portfolio was $10.2 million for the second quarter of 2023, compared to $0.5 million in the first quarter of 2023, mainly due to an increased uncertainty in the CRE price index and, to a lesser extent, the effect of the increase in the size of the loan portfolio. The results for the second quarter of 2023 also reflect a $1.2 million incremental provision associated to the aforementioned commercial and industrial participated loan in the Florida region in the power generation industry.

    • Provision for credit losses for the residential mortgage loan portfolio was a net benefit of $3.5 million for the second quarter of 2023, compared to an expense of $0.1 million in the first quarter of 2023. The net benefit recognized during the second quarter of 2023 was mainly due to a more favorable economic outlook in the projection of certain forecasted macroeconomic variables, such as the Regional Home Price Index.

    • Provision for credit losses for the consumer loans and finance leases portfolio was $14.1 million for the second quarter of 2023, compared to $15.7 million in the first quarter of 2023. The decrease in provision expense is primarily related to the previously mentioned updates in macroeconomic variables.

  • The ratio of the ACL for loans and finance leases to total loans held for investment was 2.28% as of June 30, 2023, compared to 2.29% as of March 31, 2023. The ratio of the total ACL for loans and finance leases to nonaccrual loans held for investment was 326% as of June 30, 2023, compared to 298% as of March 31, 2023.

Net Charge-Offs

The following table presents ratios of annualized net charge-offs (recoveries) to average loans held-in-portfolio for the last five quarters:

 

Quarter Ended

 

 

June 30,2023

 

March 31, 2023

 

December 31, 2022

 

September 30, 2022

 

June 30,2022

 

 

 

 

 

 

 

 

 

 

 

 

Residential mortgage

0.06%

 

0.07%

 

0.07%

 

0.13%

 

0.11%

 

Commercial mortgage

0.01%

 

-0.03%

 

0.00%

 

-0.01%

 

-0.22%

 

Commercial and Industrial

0.87%

 

0.00%

 

0.19%

 

-0.07%

 

-0.07%

 

Construction

-0.99%

 

-0.17%

 

-1.82%

 

0.07%

 

-0.09%

 

Consumer loans and finance leases

1.51%

 

1.54%

 

1.44%

 

1.05%

 

0.91%

 

Total loans

0.67%

 

0.46%

 

0.46%

 

0.31%

 

0.21%

 

The ratios above are based on annualized net charge-offs and are not necessarily indicative of the results expected in subsequent periods.

Net charge-offs were $19.3 million for the second quarter of 2023, or an annualized 0.67% of average loans, compared to $13.3 million, or an annualized 0.46% of average loans, in the first quarter of 2023. The increase of $6.0 million in net charge-offs was driven by a $6.1 million increase in commercial and construction loans net charge-offs mainly related to the aforementioned $6.2 million charge-off recorded during the second quarter of 2023.

Allowance for Credit Losses for Unfunded Loan Commitments

As of June 30, 2023, the ACL for off-balance sheet credit exposures increased to $4.9 million, compared to $4.2 million as of March 31, 2023, mainly in the construction loan portfolio, due to a deterioration in the forecasted CRE Price Index.

Allowance for Credit Losses for Debt Securities

As of June 30, 2023, the ACL for debt securities was $8.8 million, of which $8.4 million is related to Puerto Rico municipal bonds classified as held-to-maturity, compared to $8.0 million and $7.6 million, respectively, as of March 31, 2023. The increase in the ACL of held-to-maturity debt securities was mostly driven by higher exposure risk associated to the rising interest rate environment.

LIQUIDITY

Cash and cash equivalents increased by $223.9 million to $1.0 billion as of June 30, 2023. When adding $2.2 billion of free high-quality liquid securities that could be liquidated or pledged within one day, total core liquidity amounted to $3.2 billion as of June 30, 2023, or 16.70% of total assets, compared to $3.2 billion, or 16.77% of total assets as of March 31, 2023. In addition, as of June 30, 2023, the Corporation had $980.9 million available for credit with the FHLB based on the value of collateral pledged with the FHLB. As such, the basic liquidity ratio (which includes cash, free high-quality liquid assets such as U.S. government and government sponsored entities’ obligations that could be liquidated or pledged within one day, and available secured lines of credit with the FHLB to total assets) was approximately 21.82% as of June 30, 2023, compared to 21.42% as of March 31, 2023.

In addition to the aforementioned available credit from the FHLB, the Corporation also maintains borrowing capacity at the FED Discount Window Program. The Corporation does not consider borrowing capacity from the FED Discount Window as a primary source of liquidity but had approximately $1.4 billion available for funding under the FED’s Borrower-In-Custody (“BIC”) Program as of June 30, 2023. Also, the Corporation has access to financing with other counterparties through repurchase agreements and is enrolled in the FED’s Bank Term Funding Program. Combined, as of June 30, 2023, the Corporation had $5.6 billion available to meet liquidity needs.

The Corporation’s total deposits, excluding brokered CDs, amounted to $16.5 billion as of June 30, 2023, compared to $15.8 billion as of March 31, 2023, including government deposits amounting to $3.4 billion and $2.7 billion, respectively, which are fully collateralized. As of June 30, 2023, $4.7 billion of these deposits are uninsured, which represent 28.79% of total deposits, compared to $4.8 billion, or 30.13% of total deposits, as of March 31, 2023. Brokered CDs amounted to $363.6 million as of June 30, 2023, compared to $252.9 million as of March 31, 2023. Refer to Table 11 for additional information about the deposits composition.

STATEMENT OF FINANCIAL CONDITION

Total assets were approximately $19.2 billion as of June 30, 2023, up $175.4 million from March 31, 2023.

The following variances within the main components of total assets are noted:

  • A $223.9 million increase in cash and cash equivalents mainly related to the $767.7 million net increase in deposits, partially offset by the $546.1 million decrease in borrowings.

  • A $181.9 million decrease in investment securities, mainly driven by principal repayments of approximately $111.7 million primarily on U.S. agencies MBS, a $54.8 million decrease in the fair value of available-for-sale debt securities attributable to changes in market interest rates and a $19.5 million decrease in investments on FHLB stock tied to the decline in short-term advances from the FHLB.

  • A $140.4 million increase in total loans. The variance consisted of increases of $79.3 million in the Puerto Rico region, $42.5 million in the Virgin Islands region, and $18.6 million in the Florida region. On a portfolio basis, the variance consisted of increases of $88.2 million in consumer loans, primarily auto loans and finance leases, and $70.8 million in commercial and construction loans, partially offset by a decrease of $18.6 million in residential mortgage loans. The increase in commercial and construction loans was mainly associated with a $33.2 million increase in the balance of floor plan lines of credit in the Puerto Rico region and the origination of a $47.0 million line of credit facility extended to a public corporation in the Virgin Islands region.

    Total loan originations, including refinancings, renewals, and draws from existing commitments (excluding credit card utilization activity), amounted to $1.1 billion in the second quarter of 2023, an increase of $8.9 million compared to the first quarter of 2023. The growth in total loan originations consisted of increases of $37.9 million in residential mortgage loan originations and $11.1 million in consumer loan originations, partially offset by a $40.1 million decrease in commercial and construction loan originations.

    Total loan originations in the Puerto Rico region amounted to $834.7 million in the second quarter of 2023, a decrease of $75.0 million, compared to $909.7 million in the first quarter of 2023. The $75.0 million decline in total loan originations consisted of: (i) a $112.3 million decrease in commercial and construction loan originations mainly due to three commercial and industrial loans over $20 million originated in the previous quarter, partially offset by increases of $27.0 million in residential mortgage loan originations and $10.3 million in consumer loan originations.

    Total loan originations in the Virgin Islands region amounted to $79.7 million in the second quarter of 2023, compared to $19.0 million in the first quarter of 2023. The $60.7 million growth in total loan originations consisted of increases of $59.7 million in commercial and construction loan originations driven by the aforementioned $47.0 million origination of a line of credit facility to a public corporation, and $1.1 million in consumer loan originations, partially offset by a $0.1 million decrease in residential mortgage loan originations.

    Total loan originations in the Florida region amounted to $168.9 million in the second quarter of 2023, compared to $145.7 million in the first quarter of 2023. The $23.2 million growth in total loan originations consisted of increases of $12.5 million in commercial and construction loan originations and $11.0 million in residential mortgage loan originations, partially offset by a $0.3 million decrease in consumer loan originations.

Total liabilities were approximately $17.8 billion as of June 30, 2023, an increase of $183.0 million from March 31, 2023.

The increase in total liabilities was mainly due to:

  • A $767.7 million increase in total deposits driven by a $917.8 million increase in interest-bearing deposits, partially offset by a $150.1 million decrease in non-interest-bearing deposits. As of June 30, 2023, non-interest-bearing deposits represented 35% of total deposits, compared to 38% as of March 31, 2023. The increase in total deposits included the following significant variances:

    • A $761.3 million increase in government deposits, consisting of growth of $698.0 million in the Puerto Rico region, $62.5 million in the Virgin Islands region, and $0.8 million in the Florida region. Most of the increase in the Puerto Rico region was related to higher balances of interest-bearing transactional accounts.

    • A $110.7 million increase in brokered CDs. The increase reflects the effect of new issuances amounting to $264.4 million with an all-in cost of 5.14%, partially offset by approximately $153.7 million of maturing brokered CDs, with an all-in cost of 4.80%, that were paid off during the second quarter of 2023.

    • A $104.3 million decrease in deposits, excluding brokered CDs and government deposits, reflecting reductions of $77.3 million in the Puerto Rico region, $22.5 million in the Florida region, and $4.5 million in the Virgin Islands region. The decrease in total deposits, excluding brokered CDs and government deposits, is net of a $149.4 million increase in time deposits.

Partially offset by:

  • A $546.1 million decrease in borrowings, reflecting repayments of $425.0 million in short-term FHLB advances at an average cost of 5.04%, a $99.0 million decline in short-term repurchase agreements, and the repurchase of $21.4 million in junior subordinated debentures.

Total stockholders’ equity amounted to $1.4 billion as of June 30, 2023, a decrease of $7.6 million from March 31, 2023, mainly driven by the $54.8 million decrease in the fair value of available-for-sale debt securities due to changes in market interest rates recognized as part of accumulated other comprehensive loss and $25.3 million in common stock dividends declared in the second quarter of 2023, partially offset by earnings generated in the second quarter of 2023.

As of June 30, 2023, capital ratios exceeded the required regulatory levels for bank holding companies and well-capitalized banks. The Corporation’s estimated CET1 capital, tier 1 capital, total capital and leverage ratios under the Basel III rules were 16.64%, 16.64%, 19.15%, and 10.73%, respectively, as of June 30, 2023, compared to CET1 capital, tier 1 capital, total capital, and leverage ratios of 16.33%, 16.33%, 19.02%, and 10.57%, respectively, as of March 31, 2023.

Meanwhile, estimated CET1 capital, tier 1 capital, total capital and leverage ratios of our banking subsidiary, FirstBank, were 16.54%, 17.34%, 18.59%, and 11.18%, respectively, as of June 30, 2023, compared to CET1 capital, tier 1 capital, total capital and leverage ratios of 16.65%, 17.45%, 18.71%, and 11.29%, respectively, as of March 31, 2023.

Tangible Common Equity (Non-GAAP)

On a non-GAAP basis, the Corporation’s tangible common equity ratio decreased to 7.03% as of June 30, 2023, compared to 7.12% as of March 31, 2023.

The following table presents a reconciliation of the Corporation’s tangible common equity and tangible assets to the most comparable GAAP items as of the indicated dates:

 

June 30,2023

 

March 31, 2023

 

December 31, 2022

 

September 30, 2022

 

June 30,2022

(In thousands, except ratios and per share information)

 

 

 

 

 

 

 

 

 

Tangible Equity:

 

 

 

 

 

 

 

 

 

Total common equity – GAAP

$

1,397,999

 

 

$

1,405,593

 

 

$

1,325,540

 

 

$

1,265,333

 

 

$

1,557,916

 

Goodwill

 

(38,611

)

 

 

(38,611

)

 

 

(38,611

)

 

 

(38,611

)

 

 

(38,611

)

Purchased credit card relationship intangible

 

(17

)

 

 

(86

)

 

 

(205

)

 

 

(376

)

 

 

(599

)

Core deposit intangible

 

(17,075

)

 

 

(18,987

)

 

 

(20,900

)

 

 

(22,818

)

 

 

(24,736

)

Insurance customer relationship intangible

 

 

 

 

 

 

 

(13

)

 

 

(51

)

 

 

(89

)

 

 

 

 

 

 

 

 

 

 

Tangible common equity – non-GAAP

$

1,342,296

 

 

$

1,347,909

 

 

$

1,265,811

 

 

$

1,203,477

 

 

$

1,493,881

 

 

 

 

 

 

 

 

 

 

 

Tangible Assets:

 

 

 

 

 

 

 

 

 

Total assets – GAAP

$

19,152,455

 

 

$

18,977,114

 

 

$

18,634,484

 

 

$

18,442,034

 

 

$

19,531,635

 

Goodwill

 

(38,611

)

 

 

(38,611

)

 

 

(38,611

)

 

 

(38,611

)

 

 

(38,611

)

Purchased credit card relationship intangible

 

(17

)

 

 

(86

)

 

 

(205

)

 

 

(376

)

 

 

(599

)

Core deposit intangible

 

(17,075

)

 

 

(18,987

)

 

 

(20,900

)

 

 

(22,818

)

 

 

(24,736

)

Insurance customer relationship intangible

 

 

 

 

 

 

 

(13

)

 

 

(51

)

 

 

(89

)

 

 

 

 

 

 

 

 

 

 

Tangible assets – non-GAAP

$

19,096,752

 

 

$

18,919,430

 

 

$

18,574,755

 

 

$

18,380,178

 

 

$

19,467,600

 

 

 

 

 

 

 

 

 

 

 

Common shares outstanding

 

179,757

 

 

 

179,789

 

 

 

182,709

 

 

 

186,258

 

 

 

191,626

 

 

 

 

 

 

 

 

 

 

 

Tangible common equity ratio – non-GAAP

 

7.03

%

 

 

7.12

%

 

 

6.81

%

 

 

6.55

%

 

 

7.67

%

Tangible book value per common share – non-GAAP

$

7.47

 

 

$

7.50

 

 

$

6.93

 

 

$

6.46

 

 

$

7.80

 

 

 

 

 

 

 

 

 

 

 

Exposure to Puerto Rico Government

As of June 30, 2023, the Corporation had $344.3 million of direct exposure to the Puerto Rico government, its municipalities, and public corporations, an increase of $4.3 million when compared to $340.0 million as of March 31, 2023. As of June 30, 2023, approximately $186.2 million of the exposure consisted of loans and obligations of municipalities in Puerto Rico that are supported by assigned property tax revenues and for which, in most cases, the good faith, credit, and unlimited taxing power of the applicable municipality have been pledged to their repayment, and $113.2 million consisted of loans and obligations which are supported by one or more specific sources of municipal revenues. The Corporation’s total direct exposure to the Puerto Rico government also included $9.5 million in a loan extended to an affiliate of the Puerto Rico Electric Power Authority and $32.1 million in loans to agencies of Puerto Rico public corporations. In addition, the total direct exposure included obligations of the Puerto Rico government, specifically a residential pass-through MBS issued by the PRHFA, at an amortized cost of $3.3 million (fair value of $2.1 million as of June 30, 2023), included as part of the Corporation’s available-for-sale debt securities portfolio. This residential pass-through MBS issued by the PRHFA is collateralized by certain second mortgages and had an unrealized loss of $1.1 million as of June 30, 2023, of which $0.3 million is due to credit deterioration.

The aforementioned exposure to municipalities in Puerto Rico included $166.1 million of financing arrangements with Puerto Rico municipalities that were issued in bond form but underwritten as loans with features that are typically found in commercial loans. These bonds are accounted for as held-to-maturity debt securities. As of June 30, 2023, the ACL for these securities was $8.4 million, compared to $7.6 million as of March 31, 2023.

As of June 30, 2023, the Corporation had $2.9 billion of public sector deposits in Puerto Rico, compared to $2.2 billion as of March 31, 2023. Approximately 21% of the public sector deposits as of June 30, 2023, were from municipalities and municipal agencies in Puerto Rico, and 79% were from public corporations, the Puerto Rico central government and agencies, and U.S. federal government agencies in Puerto Rico.

Conference Call / Webcast Information

First BanCorp.’s senior management will host an earnings conference call and live webcast on Thursday, July 27, 2023, at 10:00 a.m. (Eastern Time). The call may be accessed via a live Internet webcast through the investor relations section of the Corporation’s web site, fbpinvestor.com, or through a dial-in telephone number at (833) 470-1428 or (404) 975-4839 for international callers. The participant access code is 640793. The Corporation recommends that listeners go to the web site at least 15 minutes prior to the call to download and install any necessary software. Following the webcast presentation, a question and answer session will be made available to research analysts and institutional investors. A replay of the webcast will be archived in the investor relations section of First BanCorp.’s website, fbpinvestor.com, until July 27, 2024. A telephone replay will be available one hour after the end of the conference call through August 26, 2023, at (866) 813-9403. The replay access code is 486480.

Safe Harbor

This press release may contain “forward-looking statements” concerning the Corporation’s future economic, operational, and financial performance. The words or phrases “expect,” “anticipate,” “intend,” “should,” “would,” “will,” “plans,” “forecast,” “believe,” and similar expressions are meant to identify “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by such sections. The Corporation cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date hereof, and advises readers that any such forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties, estimates, and assumptions by us that are difficult to predict. Various factors, some of which are beyond our control, including, but not limited to, the uncertainties more fully discussed in Part I, Item 1A, “Risk Factors” of the Corporation’s Annual Report on Form 10-K for the year ended December 31, 2022, Part II, Item 1A, “Risk Factors” of the Corporation’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023, and the following, could cause actual results to differ materially from those expressed in, or implied by, such forward-looking statements: the impacts of rising interest rates and inflation on the Corporation, including a decrease in demand for new loan originations and refinancings, increased competition for borrowers, attrition in deposits, a reduction in the fair value of the Corporation’s debt securities portfolio, and an increase in non-interest expenses which would impact the Corporation’s earnings and may adversely impact origination volumes, liquidity, and financial performance; volatility in the financial services industry, including failures or rumored failures of other depository institutions, and actions taken by governmental agencies to stabilize the financial system, which could result in, among other things, bank deposit runoffs and liquidity constraints; the effect of continued changes in the fiscal and monetary policies and regulations of the U.S. federal government, the Puerto Rico government and other governments, including those determined by the Federal Reserve Board, the Federal Reserve Bank of New York, the Federal Deposit Insurance Corporation (“FDIC”), government-sponsored housing agencies and regulators in Puerto Rico and the U.S. and British Virgin Islands; uncertainty as to the ability of FirstBank to retain its core deposits and generate sufficient cash flow through its wholesale funding sources, such as securities sold under agreements to repurchase, FHLB advances, and brokered CDs, which in turn affects its ability to make dividend payments to the Corporation and could result in selling certain investment securities portfolio at a loss; adverse changes in general economic conditions in Puerto Rico, the U.S., and the U.S. and British Virgin Islands, including in the interest rate environment, unemployment rates, market liquidity, housing absorption rates, real estate markets, and U.S. capital markets, which may affect funding sources, loan portfolio performance and credit quality, market prices of investment securities, and demand for the Corporation’s products and services, and which may reduce the Corporation’s revenues and earnings and the value of the Corporation’s assets; the impact of government financial assistance for hurricane recovery and other disaster relief on economic activity in Puerto Rico, and the timing and pace of disbursements of funds earmarked for disaster relief; the ability of the Corporation, FirstBank, and third-party service providers to identify and prevent cyber-security incidents, such as data security breaches, ransomware, malware, “denial of service” attacks, “hacking,” identity theft, and state-sponsored cyberthreats, and the occurrence of and response to any incidents that occur, such as an April 2023 security incident at one of our third-party vendors, which may result in misuse or misappropriation of confidential or proprietary information, disruption, or damage to our systems or those of third-party service providers, increased costs and losses or an adverse effect to our reputation; general competitive factors and other market risks as well as the implementation of strategic growth opportunities, including risks, uncertainties, and other factors or events related to any business acquisitions or dispositions; uncertainty as to the implementation of the debt restructuring plan of Puerto Rico and the fiscal plan for Puerto Rico as certified on April 3, 2023, by the oversight board established by the Puerto Rico Oversight, Management, and Economic Stability Act, or any revisions to it, on our clients and loan portfolios, and any potential impact from future economic or political developments and tax regulations in Puerto Rico; the impact of changes in accounting standards, or assumptions in applying those standards, on forecasts of economic variables considered for the determination of the ACL; the ability of FirstBank to realize the benefits of its net deferred tax assets; environmental, social, and governance matters, including our climate-related initiatives and commitments; the impacts of natural or man-made disasters, widespread health emergencies, geopolitical conflicts (including the ongoing conflict in Ukraine), terrorist attacks, or other catastrophic external events, including impacts of such events on general economic conditions and on the Corporation’s assumptions regarding forecasts of economic variables; the effect of changes in the interest rate environment, including any adverse change in the Corporation’s ability to attract and retain clients and gain acceptance from current and prospective customers for new products and services, including those related to the offering of digital banking and financial services; the risk that additional portions of the unrealized losses in the Corporation’s debt securities portfolio are determined to be credit-related, resulting in additional charges to the provision for credit losses on the Corporation’s available-for-sale debt securities portfolio; the impacts of applicable legislative, tax, or regulatory changes on the Corporation’s financial condition or performance; the risk of possible failure or circumvention of the Corporation’s internal controls and procedures and the risk that the Corporation’s risk management policies may not be adequate; the risk that the FDIC may further increase the deposit insurance premium and/or require special assessments, causing an additional increase in the Corporation’s non-interest expenses; any need to recognize impairments on the Corporation’s financial instruments, goodwill, and other intangible assets; the risk that the impact of the occurrence of any of these uncertainties on the Corporation’s capital would preclude further growth of FirstBank and preclude the Corporation’s Board of Directors from declaring dividends; and uncertainty as to whether FirstBank will be able to continue to satisfy its regulators regarding, among other things, its asset quality, liquidity plans, maintenance of capital levels, and compliance with applicable laws, regulations and related requirements. The Corporation does not undertake, and specifically disclaims any obligation to update any “forward-looking statements” to reflect occurrences or unanticipated events or circumstances after the date of such statements, except as required by the federal securities laws.

About First BanCorp.

First BanCorp. is the parent corporation of FirstBank Puerto Rico, a state-chartered commercial bank with operations in Puerto Rico, the U.S., and the British Virgin Islands and Florida, and of FirstBank Insurance Agency. Among the subsidiaries of FirstBank Puerto Rico are First Federal Finance Corp. and First Express, both small loan companies. First BanCorp.’s shares of common stock trade on the New York Stock Exchange under the symbol FBP. Additional information about First BanCorp. may be found at www.1firstbank.com.

EXHIBIT A

Table 1 – Condensed Consolidated Statements of Financial Condition

 

As of

 

June 30, 2023

 

March 31, 2023

 

December 31, 2022

(In thousands, except for share information)

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

 

 

Cash and due from banks

$

1,046,534

 

 

$

822,542

 

 

$

478,480

 

Money market investments:

 

 

 

 

 

 

 

 

Time deposits with other financial institutions

 

300

 

 

 

300

 

 

 

300

 

Other short-term investments

 

700

 

 

 

759

 

 

 

1,725

 

Total money market investments

 

1,000

 

 

 

1,059

 

 

 

2,025

 

Debt securities available for sale, at fair value (ACL of $433 as of June 30, 2023; $449 as of March 31, 2023; and $458 as of December 31, 2022)

 

5,433,369

 

 

 

5,589,256

 

 

 

5,599,520

 

Debt securities held to maturity, at amortized cost, net of ACL of $8,401 as of June 30, 2023; $7,646 as of March 31, 2023; and $8,286 as of December 31, 2022 (fair value of $410,181 as of June 30, 2023; $419,752 as of March 31, 2023; and $427,115 as of December 31, 2022)

 

416,325

 

 

 

423,749

 

 

 

429,251

 

Total debt securities

 

5,849,694

 

 

 

6,013,005

 

 

 

6,028,771

 

Equity securities

 

48,101

 

 

 

66,714

 

 

 

55,289

 

Total investment securities

 

5,897,795

 

 

 

6,079,719

 

 

 

6,084,060

 

Loans, net of ACL of $267,058 as of June 30, 2023; $265,567 as of March 31, 2023; and $260,464 as of December 31, 2022

 

11,452,257

 

 

 

11,312,418

 

 

 

11,292,361

 

Loans held for sale, at lower of cost or market

 

14,295

 

 

 

15,183

 

 

 

12,306

 

Total loans, net

 

11,466,552

 

 

 

11,327,601

 

 

 

11,304,667

 

Accrued interest receivable on loans and investments

 

70,368

 

 

 

63,841

 

 

 

69,730

 

Premises and equipment, net

 

146,640

 

 

 

137,580

 

 

 

142,935

 

OREO

 

31,571

 

 

 

32,862

 

 

 

31,641

 

Deferred tax asset, net

 

153,925

 

 

 

154,780

 

 

 

155,584

 

Goodwill

 

38,611

 

 

 

38,611

 

 

 

38,611

 

Other intangible assets

 

17,092

 

 

 

19,073

 

 

 

21,118

 

Other assets

 

282,367

 

 

 

299,446

 

 

 

305,633

 

Total assets

$

19,152,455

 

 

$

18,977,114

 

 

$

18,634,484

 

LIABILITIES

 

 

 

 

 

 

 

 

Deposits:

 

 

 

 

 

 

 

 

Non-interest-bearing deposits

$

5,874,261

 

 

$

6,024,304

 

 

$

6,112,884

 

Interest-bearing deposits

 

10,945,431

 

 

 

10,027,661

 

 

 

10,030,583

 

Total deposits

 

16,819,692

 

 

 

16,051,965

 

 

 

16,143,467

 

Securities sold under agreements to repurchase

 

73,934

 

 

 

172,982

 

 

 

75,133

 

Advances from the FHLB

 

500,000

 

 

 

925,000

 

 

 

675,000

 

Other borrowings

 

161,700

 

 

 

183,762

 

 

 

183,762

 

Accounts payable and other liabilities

 

199,130

 

 

 

237,812

 

 

 

231,582

 

Total liabilities

 

17,754,456

 

 

 

17,571,521

 

 

 

17,308,944

 

STOCKHOLDERSʼ EQUITY

 

 

 

 

 

 

 

 

Common stock, $0.10 par value, 223,663,116 shares issued (June 30, 2023 – 179,756,622 shares outstanding; March 31, 2023 – 179,788,698 shares outstanding; and December 31, 2022 – 182,709,059 shares outstanding)

 

22,366

 

 

 

22,366

 

 

 

22,366

 

Additional paid-in capital

 

962,229

 

 

 

959,912

 

 

 

970,722

 

Retained earnings

 

1,733,497

 

 

 

1,688,176

 

 

 

1,644,209

 

Treasury stock, at cost (June 30, 2023 – 43,906,494 shares; March 31, 2023 – 43,874,418 shares; December 31, 2022 – 40,954,057 shares)

 

(547,706

)

 

 

(547,311

)

 

 

(506,979

)

Accumulated other comprehensive loss

 

(772,387

)

 

 

(717,550

)

 

 

(804,778

)

Total stockholdersʼ equity

 

1,397,999

 

 

 

1,405,593

 

 

 

1,325,540

 

Total liabilities and stockholdersʼ equity

$

19,152,455

 

 

$

18,977,114

 

 

$

18,634,484

 

Table 2 – Condensed Consolidated Statements of Income

 

 

 

 

 

 

Quarter Ended

Six-Month Period Ended

 

June 30, 2023

March 31, 2023

June 30, 2022

June 30, 2023

June 30, 2022

(In thousands, except per share information)

 

 

 

 

 

Net interest income:

 

 

 

 

 

Interest income

$

252,204

 

$

242,396

 

$

208,625

 

$

494,600

 

$

406,479

 

Interest expense

 

52,389

 

 

41,511

 

 

12,439

 

 

93,900

 

 

24,669

 

Net interest income

 

199,815

 

 

200,885

 

 

196,186

 

 

400,700

 

 

381,810

 

Provision for credit losses – expense (benefit):

 

 

 

 

 

Loans

 

20,770

 

 

16,256

 

 

12,665

 

 

37,026

 

 

(4,324

)

Unfunded loan commitments

 

721

 

 

(105

)

 

812

 

 

616

 

 

634

 

Debt securities

 

739

 

 

(649

)

 

(3,474

)

 

90

 

 

(109

)

Provision for credit losses – expense (benefit)

 

22,230

 

 

15,502

 

 

10,003

 

 

37,732

 

 

(3,799

)

Net interest income after provision for credit losses

 

177,585

 

 

185,383

 

 

186,183

 

 

362,968

 

 

385,609

 

 

 

 

 

 

 

Non-interest income:

 

 

 

 

 

Service charges and fees on deposit accounts

 

9,287

 

 

9,541

 

 

9,466

 

 

18,828

 

 

18,829

 

Mortgage banking activities

 

2,860

 

 

2,812

 

 

4,082

 

 

5,672

 

 

9,288

 

Card and processing income

 

11,135

 

 

10,918

 

 

10,300

 

 

22,053

 

 

19,981

 

Gain on early extinguishment of debt

 

1,605

 

 

 

 

 

 

1,605

 

 

 

Other non-interest income

 

11,384

 

 

9,247

 

 

7,093

 

 

20,631

 

 

15,701

 

Total non-interest income

 

36,271

 

 

32,518

 

 

30,941

 

 

68,789

 

 

63,799

 

 

 

 

 

 

 

Non-interest expenses:

 

 

 

 

 

Employees’ compensation and benefits

 

54,314

 

 

56,422

 

 

51,304

 

 

110,736

 

 

100,858

 

Occupancy and equipment

 

21,097

 

 

21,186

 

 

21,505

 

 

42,283

 

 

43,891

 

Business promotion

 

4,167

 

 

3,975

 

 

4,042

 

 

8,142

 

 

7,505

 

Professional service fees

 

11,596

 

 

11,973

 

 

12,036

 

 

23,569

 

 

22,630

 

Taxes, other than income taxes

 

5,124

 

 

5,112

 

 

4,689

 

 

10,236

 

 

9,707

 

Insurance and supervisory fees

 

4,495

 

 

4,501

 

 

3,769

 

 

8,996

 

 

7,677

 

Net gain on OREO operations

 

(1,984

)

 

(1,996

)

 

(1,485

)

 

(3,980

)

 

(2,205

)

Credit and debit card processing expenses

 

6,540

 

 

5,318

 

 

5,843

 

 

11,858

 

 

9,964

 

Other non-interest expenses

 

7,568

 

 

8,777

 

 

6,623

 

 

16,345

 

 

14,958

 

Total non-interest expenses

 

112,917

 

 

115,268

 

 

108,326

 

 

228,185

 

 

214,985

 

 

 

 

 

 

 

Income before income taxes

 

100,939

 

 

102,633

 

 

108,798

 

 

203,572

 

 

234,423

 

Income tax expense

 

30,284

 

 

31,935

 

 

34,103

 

 

62,219

 

 

77,128

 

 

 

 

 

 

 

Net income

$

70,655

 

$

70,698

 

$

74,695

 

$

141,353

 

$

157,295

 

 

 

 

 

 

 

Net income attributable to common stockholders

$

70,655

 

$

70,698

 

$

74,695

 

$

141,353

 

$

157,295

 

 

 

 

 

 

 

Earnings per common share:

 

 

 

 

 

Basic

$

0.39

 

$

0.39

 

$

0.38

 

$

0.79

 

$

0.80

 

Diluted

$

0.39

 

$

0.39

 

$

0.38

 

$

0.78

 

$

0.80

 

Table 3 – Selected Financial Data

 

 

Quarter Ended

 

Six-Month Period Ended

 

 

June 30, 2023

 

March 31, 2023

 

June 30, 2022

 

June 30, 2023

 

June 30, 2022

(Shares in thousands)

 

 

 

 

 

 

 

 

 

 

Per Common Share Results:

 

 

 

 

 

 

 

 

 

 

Net earnings per share – basic

 

$

0.39

 

$

0.39

 

$

0.38

 

$

0.79

 

$

0.80

 

Net earnings per share – diluted

 

$

0.39

 

$

0.39

 

$

0.38

 

$

0.78

 

$

0.80

 

Cash dividends declared

 

$

0.14

 

$

0.14

 

$

0.12

 

$

0.28

 

$

0.22

 

Average shares outstanding

 

 

178,926

 

 

180,215

 

 

194,405

 

 

179,567

 

 

196,257

 

Average shares outstanding diluted

 

 

179,277

 

 

181,236

 

 

195,366

 

 

180,253

 

 

197,441

 

Book value per common share

 

$

7.78

 

$

7.82

 

$

8.13

 

$

7.78

 

$

8.13

 

Tangible book value per common share (1)

 

$

7.47

 

$

7.50

 

$

7.80

 

$

7.47

 

$

7.80

 

Common Stock Price: End of period

 

$

12.22

 

$

11.42

 

$

12.91

 

$

12.22

 

$

12.91

 

Selected Financial Ratios (In Percent):

 

 

 

 

 

 

 

 

 

 

Profitability:

 

 

 

 

 

 

 

 

 

 

Return on Average Assets

 

 

1.51

 

 

1.55

 

 

1.52

 

 

1.53

 

 

1.59

 

Return on Average Common Equity

 

 

19.66

 

 

21.00

 

 

17.82

 

 

20.31

 

 

17.18

 

Interest Rate Spread (2)

 

 

3.58

 

 

3.84

 

 

4.01

 

 

3.71

 

 

3.89

 

Net Interest Margin (2)

 

 

4.35

 

 

4.48

 

 

4.19

 

 

4.42

 

 

4.08

 

Efficiency ratio (3)

 

 

47.83

 

 

49.39

 

 

47.69

 

 

48.60

 

 

48.25

 

Capital and Other:

 

 

 

 

 

 

 

 

 

 

Average Total Equity to Average Total Assets

 

 

7.67

 

 

7.36

 

 

8.52

 

 

7.52

 

 

9.24

 

Total capital

 

 

19.15

 

 

19.02

 

 

19.98

 

 

19.15

 

 

19.98

 

Common equity Tier 1 capital

 

 

16.64

 

 

16.33

 

 

17.23

 

 

16.64

 

 

17.23

 

Tier 1 capital

 

 

16.64

 

 

16.33

 

 

17.23

 

 

16.64

 

 

17.23

 

Leverage

 

 

10.73

 

 

10.57

 

 

10.18

 

 

10.73

 

 

10.18

 

Tangible common equity ratio (1)

 

 

7.03

 

 

7.12

 

 

7.67

 

 

7.03

 

 

7.67

 

Dividend payout ratio

 

 

35.45

 

 

35.69

 

 

31.23

 

 

35.57

 

 

27.45

 

Basic liquidity ratio (4)

 

 

21.82

 

 

21.42

 

 

28.84

 

 

21.82

 

 

28.84

 

Core liquidity ratio (5)

 

 

16.70

 

 

16.77

 

 

23.11

 

 

16.70

 

 

23.11

 

Loan to deposit ratio

 

 

69.76

 

 

72.22

 

 

65.52

 

 

69.76

 

 

65.52

 

Uninsured deposits, excluding fully collateralized deposits, to total deposits

 

 

28.79

 

 

30.13

 

 

31.89

 

 

28.79

 

 

31.89

 

Asset Quality:

 

 

 

 

 

 

 

 

 

 

Allowance for credit losses for loans and finance leases to total loans held for investment

 

 

2.28

 

 

2.29

 

 

2.25

 

 

2.28

 

 

2.25

 

Net charge-offs (annualized) to average loans outstanding

 

 

0.67

 

 

0.46

 

 

0.21

 

 

0.56

 

 

0.23

 

Provision for credit losses for loans and finance leases – expense (benefit) to net charge-offs

 

 

107.73

 

 

122.51

 

 

212.50

 

 

113.76

 

 

(34.44

)

Non-performing assets to total assets

 

 

0.63

 

 

0.68

 

 

0.76

 

 

0.63

 

 

0.76

 

Nonaccrual loans held for investment to total loans held for investment

 

 

0.70

 

 

0.77

 

 

0.88

 

 

0.70

 

 

0.88

 

Allowance for credit losses for loans and finance leases to total nonaccrual loans held for investment

 

 

325.60

 

 

297.91

 

 

254.42

 

 

325.60

 

 

254.42

 

Allowance for credit losses for loans and finance leases to total nonaccrual loans held for investment, excluding residential estate loans

 

 

547.60

 

 

503.62

 

 

462.48

 

 

547.60

 

 

462.48

 

(1)

Non-GAAP financial measures (as defined above). Refer to Statement of Financial Condition above and Table 4 below for additional information about the components and a reconciliation of these measures.

(2)

On a tax-equivalent basis and excluding changes in the fair value of derivative instruments (non-GAAP financial measure). Refer to Non-GAAP Disclosures above for additional information and a reconciliation of these measures.

(3)

Non-interest expenses to the sum of net interest income and non-interest income.

(4)

Defined as the sum of cash and cash equivalents, free high quality liquid assets that could be liquidated within one day, and available secured lines of credit with the FHLB to total assets.

(5)

Defined as the sum of cash and cash equivalents and free high quality liquid assets that could be liquidated within one day to total assets.

Table 4 – Reconciliation of Net Interest Income to Net Interest Income Excluding Valuations and on a Tax-Equivalent Basis

The following table reconciles net interest income in accordance with GAAP to net interest income excluding valuations, and net interest income on a tax-equivalent basis for the second and first quarters of 2023, the second quarter of 2022 and the six-month periods ended June 30, 2023 and 2022, respectively. The table also reconciles netinterest spread and net interest margin to these items excluding valuations, and on a tax-equivalent basis.

Quarter Ended

 

Six-Month Period Ended

(Dollars in thousands)

June 30, 2023

 

March 31, 2023

 

June 30,2022

 

 

June 30,2023

 

June 30,2022

Net Interest Income

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income – GAAP

$

252,204

 

 

$

242,396

 

 

$

208,625

 

 

 

$

494,600

 

 

$

406,479

 

Unrealized (gain) loss on derivative instruments

 

(3

)

 

 

6

 

 

 

(9

)

 

 

 

3

 

 

 

(24

)

Interest income excluding valuations non-GAAP

 

252,201

 

 

 

242,402

 

 

 

208,616

 

 

 

 

494,603

 

 

 

406,455

 

Tax-equivalent adjustment

 

5,540

 

 

 

6,347

 

 

 

9,389

 

 

 

 

11,887

 

 

 

16,608

 

Interest income on a tax-equivalent basis and excluding valuations non-GAAP

$

257,741

 

 

$

248,749

 

 

$

218,005

 

 

 

$

506,490

 

 

$

423,063

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense – GAAP

$

52,389

 

 

$

41,511

 

 

$

12,439

 

 

 

$

93,900

 

 

$

24,669

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net interest income – GAAP

$

199,815

 

 

$

200,885

 

 

$

196,186

 

 

 

$

400,700

 

 

$

381,810

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net interest income excluding valuations non-GAAP

$

199,812

 

 

$

200,891

 

 

$

196,177

 

 

 

$

400,703

 

 

$

381,786

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net interest income on a tax-equivalent basis and excluding valuations – non-GAAP

$

205,352

 

 

$

207,238

 

 

$

205,566

 

 

 

$

412,590

 

 

$

398,394

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average Balances

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loans and leases

$

11,591,516

 

 

$

11,519,399

 

 

$

11,102,310

 

 

 

$

11,555,659

 

 

$

11,104,571

 

Total securities, other short-term investments and interest-bearing cash balances

 

7,333,989

 

 

 

7,232,347

 

 

 

8,568,022

 

 

 

 

7,283,450

 

 

 

8,607,337

 

Average Interest-Earning Assets

$

18,925,505

 

 

$

18,751,746

 

 

$

19,670,332

 

 

 

$

18,839,109

 

 

$

19,711,908

 

Average Interest-Bearing Liabilities

$

11,176,385

 

 

$

10,957,892

 

 

$

11,567,228

 

 

 

$

11,067,741

 

 

$

11,390,486

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average Yield/Rate

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average yield on interest-earning assets – GAAP

 

5.35

%

 

 

5.24

%

 

 

4.25

%

 

 

 

5.29

%

 

 

4.16

%

Average rate on interest-bearing liabilities – GAAP

 

1.88

%

 

 

1.54

%

 

 

0.43

%

 

 

 

1.71

%

 

 

0.44

%

Net interest spread – GAAP

 

3.47

%

 

 

3.70

%

 

 

3.82

%

 

 

 

3.58

%

 

 

3.72

%

Net interest margin – GAAP

 

4.23

%

 

 

4.34

%

 

 

4.00

%

 

 

 

4.29

%

 

 

3.91

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average yield on interest-earning assets excluding valuations – non-GAAP

 

5.35

%

 

 

5.24

%

 

 

4.25

%

 

 

 

5.29

%

 

 

4.16

%

Average rate on interest-bearing liabilities excluding valuations – non-GAAP

 

1.88

%

 

 

1.54

%

 

 

0.43

%

 

 

 

1.71

%

 

 

0.44

%

Net interest spread excluding valuations – non-GAAP

 

3.47

%

 

 

3.70

%

 

 

3.82

%

 

 

 

3.58

%

 

 

3.72

%

Net interest margin excluding valuations – non-GAAP

 

4.23

%

 

 

4.34

%

 

 

4.00

%

 

 

 

4.29

%

 

 

3.91

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Average yield on interest-earning assets on a tax-equivalent basis and excluding valuations – non-GAAP

 

5.46

%

 

 

5.38

%

 

 

4.45

%

 

 

 

5.42

%

 

 

4.33

%

Average rate on interest-bearing liabilities

 

1.88

%

 

 

1.54

%

 

 

0.43

%

 

 

 

1.71

%

 

 

0.44

%

Net interest spread on a tax-equivalent basis and excluding valuations – non-GAAP

 

3.58

%

 

 

3.84

%

 

 

4.01

%

 

 

 

3.71

%

 

 

3.89

%

Net interest margin on a tax-equivalent basis and excluding valuations – non-GAAP

 

4.35

%

 

 

4.48

%

 

 

4.19

%

 

 

 

4.42

%

 

 

4.08

%

Table 5 – Quarterly Statement of Average Interest-Earning Assets and Average Interest-Bearing Liabilities (On a Tax-Equivalent Basis)

 

 

 

 

 

 

Average Volume

 

Interest income (1) / expense

 

Average Rate (1)

Quarter Ended

June 30,

 

March 31,

 

June 30,

 

June 30,

 

March 31,

 

June 30,

 

June 30,

 

March 31,

 

June 30,

 

2023

 

2023

 

2022

 

2023

 

2023

 

2022

 

2023

 

 

2023

 

 

2022

 

(Dollars in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest-earning assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market and other short-term investments

$

617,356

 

$

404,249

 

$

1,530,353

 

$

7,880

 

$

4,650

 

$

2,873

 

5.12

%

 

4.67

%

 

0.75

%

Government obligations (2)

 

2,909,204

 

 

2,909,976

 

 

2,922,226

 

 

10,973

 

 

10,765

 

 

10,090

 

1.51

%

 

1.50

%

 

1.38

%

Mortgage-backed securities

 

3,757,425

 

 

3,864,145

 

 

4,081,573

 

 

17,087

 

 

19,396

 

 

22,804

 

1.82

%

 

2.04

%

 

2.24

%

FHLB stock

 

36,265

 

 

40,838

 

 

21,275

 

 

780

 

 

421

 

 

251

 

8.63

%

 

4.18

%

 

4.73

%

Other investments

 

13,739

 

 

13,139

 

 

12,595

 

 

58

 

 

139

 

 

12

 

1.69

%

 

4.29

%

 

0.38

%

Total investments (3)

 

7,333,989

 

 

7,232,347

 

 

8,568,022

 

 

36,778

 

 

35,371

 

 

36,030

 

2.01

%

 

1.98

%

 

1.69

%

Residential mortgage loans

 

2,808,465

 

 

2,835,240

 

 

2,891,403

 

 

39,864

 

 

39,794

 

 

40,573

 

5.69

%

 

5.69

%

 

5.63

%

C&I and commercial mortgage loans

 

5,191,040

 

 

5,167,727

 

 

5,054,223

 

 

89,290

 

 

85,885

 

 

64,500

 

6.90

%

 

6.74

%

 

5.12

%

Construction loans

 

149,783

 

 

146,041

 

 

124,070

 

 

2,903

 

 

2,676

 

 

1,768

 

7.77

%

 

7.43

%

 

5.72

%

Finance leases

 

769,316

 

 

735,500

 

 

617,399

 

 

14,714

 

 

13,809

 

 

11,410

 

7.67

%

 

7.61

%

 

7.41

%

Consumer loans

 

2,672,912

 

 

2,634,891

 

 

2,415,215

 

 

74,192

 

 

71,214

 

 

63,724

 

11.13

%

 

10.96

%

 

10.58

%

Total loans (4) (5)

 

11,591,516

 

 

11,519,399

 

 

11,102,310

 

 

220,963

 

 

213,378

 

 

181,975

 

7.65

%

 

7.51

%

 

6.57

%

Total interest-earning assets

$

18,925,505

 

$

18,751,746

 

$

19,670,332

 

$

257,741

 

$

248,749

 

$

218,005

 

5.46

%

 

5.38

%

 

4.45

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest-bearing liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Time deposits

$

2,511,504

 

$

2,342,360

 

$

2,202,228

 

$

15,667

 

$

10,782

 

$

3,838

 

2.50

%

 

1.87

%

 

0.70

%

Brokered CDs

 

333,557

 

 

166,698

 

 

76,790

 

 

3,761

 

 

1,587

 

 

404

 

4.52

%

 

3.86

%

 

2.11

%

Other interest-bearing deposits

 

7,517,995

 

 

7,544,901

 

 

8,704,448

 

 

22,176

 

 

17,516

 

 

3,452

 

1.18

%

 

0.94

%

 

0.16

%

Securities sold under agreements to repurchase

 

101,397

 

 

91,004

 

 

200,000

 

 

1,328

 

 

1,069

 

 

1,972

 

5.25

%

 

4.76

%

 

3.95

%

Advances from the FHLB

 

534,231

 

 

629,167

 

 

200,000

 

 

6,048

 

 

7,176

 

 

1,075

 

4.54

%

 

4.63

%

 

2.16

%

Other borrowings

 

177,701

 

 

183,762

 

 

183,762

 

 

3,409

 

 

3,381

 

 

1,698

 

7.69

%

 

7.46

%

 

3.71

%

Total interest-bearing liabilities

$

11,176,385

 

$

10,957,892

 

$

11,567,228

 

$

52,389

 

$

41,511

 

$

12,439

 

1.88

%

 

1.54

%

 

0.43

%

Net interest income

 

 

 

 

 

 

 

 

 

$

205,352

 

$

207,238

 

$

205,566

 

 

 

 

 

 

Interest rate spread

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3.58

%

 

3.84

%

 

4.01

%

Net interest margin

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4.35

%

 

4.48

%

 

4.19

%

(1)

On a tax-equivalent basis. The tax-equivalent yield was estimated by dividing the interest rate spread on exempt assets by 1 less the Puerto Rico statutory tax rate of 37.5% and adding to it the cost of interest-bearing liabilities. When adjusted to a tax-equivalent basis, yields on taxable and exempt assets are comparable. Changes in the fair value of derivative instruments are excluded from interest income because the changes in valuation do not affect interest paid or received. Refer to Non-GAAP Disclosures and Table 4 above for additional information and a reconciliation of these measures.

(2)

Government obligations include debt issued by government-sponsored agencies.

(3)

Unrealized gains and losses on available-for-sale debt securities are excluded from the average volumes.

(4)

Average loan balances include the average of non-performing loans.

(5)

Interest income on loans includes $2.9 million, $3.1 million, and $3.0 million for the quarters ended June 30, 2023, March 31, 2023, and June 30, 2022, respectively, of income from prepayment penalties and late fees related to the Corporation’s loan portfolio.

Table 6 – Year-to-Date Statement of Average Interest-Earning Assets and Average Interest-Bearing Liabilities (On a Tax-Equivalent Basis)

 

 

Average Volume

 

Interest income (1) / expense

 

Average Rate (1)

Six-Month Period Ended

June 30, 2023

 

June 30, 2022

 

June 30, 2023

 

June 30, 2022

 

June 30, 2023

 

June 30, 2022

(Dollars in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest-earning assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market and other short-term investments

$

511,392

 

$

1,682,216

 

$

12,530

 

$

3,693

 

4.94

%

 

0.44

%

Government obligations (2)

 

2,909,587

 

 

2,829,675

 

 

21,738

 

 

18,322

 

1.51

%

 

1.31

%

Mortgage-backed securities

 

3,810,491

 

 

4,061,883

 

 

36,483

 

 

42,224

 

1.93

%

 

2.10

%

FHLB stock

 

38,539

 

 

21,370

 

 

1,201

 

 

538

 

6.28

%

 

5.08

%

Other investments

 

13,441

 

 

12,193

 

 

197

 

 

33

 

2.96

%

 

0.55

%

Total investments (3)

 

7,283,450

 

 

8,607,337

 

 

72,149

 

 

64,810

 

2.00

%

 

1.52

%

Residential mortgage loans

 

2,821,779

 

 

2,926,236

 

 

79,658

 

 

81,260

 

5.69

%

 

5.60

%

C&I and commercial mortgage loans

 

5,179,448

 

 

5,078,910

 

 

175,175

 

 

126,504

 

6.82

%

 

5.02

%

Construction loans

 

147,923

 

 

119,427

 

 

5,579

 

 

3,292

 

7.61

%

 

5.56

%

Finance leases

 

752,501

 

 

602,880

 

 

28,523

 

 

22,322

 

7.64

%

 

7.47

%

Consumer loans

 

2,654,008

 

 

2,377,118

 

 

145,406

 

 

124,875

 

11.05

%

 

10.59

%

Total loans (4) (5)

 

11,555,659

 

 

11,104,571

 

 

434,341

 

 

358,253

 

7.58

%

 

6.51

%

Total interest-earning assets

$

18,839,109

 

$

19,711,908

 

$

506,490

 

$

423,063

 

5.42

%

 

4.33

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest-bearing liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Time deposits

$

2,427,399

 

$

2,282,192

 

$

26,449

 

$

8,259

 

2.20

%

 

0.73

%

Brokered CDs

 

250,588

 

 

84,210

 

 

5,348

 

 

881

 

4.30

%

 

2.11

%

Other interest-bearing deposits

 

7,531,374

 

 

8,419,880

 

 

39,692

 

 

6,206

 

1.06

%

 

0.15

%

Securities sold under agreements to repurchase

 

96,229

 

 

220,442

 

 

2,397

 

 

4,154

 

5.02

%

 

3.80

%

Advances from the FHLB

 

581,436

 

 

200,000

 

 

13,224

 

 

2,138

 

4.59

%

 

2.16

%

Other borrowings

 

180,715

 

 

183,762

 

 

6,790

 

 

3,031

 

7.58

%

 

3.33

%

Total interest-bearing liabilities

$

11,067,741

 

$

11,390,486

 

$

93,900

 

$

24,669

 

1.71

%

 

0.44

%

Net interest income

 

 

 

 

 

 

$

412,590

 

$

398,394

 

 

 

 

Interest rate spread

 

 

 

 

 

 

 

 

 

 

 

 

3.71

%

 

3.89

%

Net interest margin

 

 

 

 

 

 

 

 

 

 

 

 

4.42

%

 

4.08

%

(1)

On a tax-equivalent basis. The tax-equivalent yield was estimated by dividing the interest rate spread on exempt assets by 1 less the Puerto Rico statutory tax rate of 37.5% and adding to it the cost of interest-bearing liabilities. When adjusted to a tax-equivalent basis, yields on taxable and exempt assets are comparable. Changes in the fair value of derivative instruments are excluded from interest income because the changes in valuation do not affect interest paid or received. Refer to Non-GAAP Disclosures and Table 4 above for additional information and a reconciliation of these measures.

(2)

Government obligations include debt issued by government-sponsored agencies.

(3)

Unrealized gains and losses on available-for-sale debt securities are excluded from the average volumes.

(4)

Average loan balances include the average of non-performing loans.

(5)

Interest income on loans includes $6.0 million and $5.6 million for the six-month periods ended June 30, 2023 and 2022, respectively, of income from prepayment penalties and late fees related to the Corporation’s loan portfolio.

Table 7 – Loan Portfolio by Geography

 

 

As of June 30,2023

 

Puerto Rico

 

Virgin Islands

 

United States

 

Consolidated

(In thousands)

 

 

Residential mortgage loans

$

2,179,539

 

$

172,771

 

$

441,480

 

$

2,793,790

 

 

 

 

 

 

 

 

 

 

 

 

Commercial loans:

 

 

 

 

 

 

 

 

 

 

 

Commercial mortgage loans

 

1,734,514

 

 

65,775

 

 

519,780

 

 

2,320,069

Commercial and Industrial loans

 

1,902,803

 

 

108,971

 

 

934,427

 

 

2,946,201

Construction loans

 

65,427

 

 

3,792

 

 

94,779

 

 

163,998

Commercial loans

 

3,702,744

 

 

178,538

 

 

1,548,986

 

 

5,430,268

 

 

 

 

 

 

 

 

 

 

 

 

Finance leases

 

790,711

 

 

 

 

 

 

790,711

 

 

 

 

 

 

 

 

 

 

 

 

Consumer loans

 

2,630,665

 

 

66,078

 

 

7,803

 

 

2,704,546

Loans held for investment

 

9,303,659

 

 

417,387

 

 

1,998,269

 

 

11,719,315

 

 

 

 

 

 

 

 

 

 

 

 

Loans held for sale

 

14,094

 

 

201

 

 

 

 

14,295

Total loans

$

9,317,753

 

$

417,588

 

$

1,998,269

 

$

11,733,610

 

 

 

 

 

 

 

 

 

 

 

 

 

As of March 31, 2023

 

Puerto Rico

 

Virgin Islands

 

United States

 

Consolidated

(In thousands)

 

 

Residential mortgage loans

$

2,205,659

 

$

176,123

 

$

429,746

 

$

2,811,528

 

 

 

 

 

 

 

 

 

 

 

 

Commercial loans:

 

 

 

 

 

 

 

 

 

 

 

Commercial mortgage loans

 

1,766,479

 

 

62,694

 

 

524,486

 

 

2,353,659

Commercial and Industrial loans

 

1,872,215

 

 

69,013

 

 

920,961

 

 

2,862,189

Construction loans

 

44,297

 

 

3,898

 

 

95,469

 

 

143,664

Commercial loans

 

3,682,991

 

 

135,605

 

 

1,540,916

 

 

5,359,512

 

 

 

 

 

 

 

 

 

 

 

 

Finance leases

 

755,482

 

 

 

 

 

 

755,482

 

 

 

 

 

 

 

 

 

 

 

 

Consumer loans

 

2,579,532

 

 

63,231

 

 

8,700

 

 

2,651,463

Loans held for investment

 

9,223,664

 

 

374,959

 

 

1,979,362

 

 

11,577,985

 

 

 

 

 

 

 

 

 

 

 

 

Loans held for sale

 

14,830

 

 

 

 

353

 

 

15,183

Total loans

$

9,238,494

 

$

374,959

 

$

1,979,715

 

$

11,593,168

 

 

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2022

 

Puerto Rico

 

Virgin Islands

 

United States

 

Consolidated

(In thousands)

 

 

Residential mortgage loans

$

2,237,983

 

$

179,917

 

$

429,390

 

$

2,847,290

 

 

 

 

 

 

 

 

 

 

 

 

Commercial loans:

 

 

 

 

 

 

 

 

 

 

 

Commercial mortgage loans

 

1,768,890

 

 

65,314

 

 

524,647

 

 

2,358,851

Commercial and Industrial loans

 

1,791,235

 

 

68,874

 

 

1,026,154

 

 

2,886,263

Construction loans

 

30,529

 

 

4,243

 

 

98,181

 

 

132,953

Commercial loans

 

3,590,654

 

 

138,431

 

 

1,648,982

 

 

5,378,067

 

 

 

 

 

 

 

 

 

 

 

 

Finance leases

 

718,230

 

 

 

 

 

 

718,230

 

 

 

 

 

 

 

 

 

 

 

 

Consumer loans

 

2,537,840

 

 

61,419

 

 

9,979

 

 

2,609,238

Loans held for investment

 

9,084,707

 

 

379,767

 

 

2,088,351

 

 

11,552,825

 

 

 

 

 

 

 

 

 

 

 

 

Loans held for sale

 

12,306

 

 

 

 

 

 

12,306

Total loans

$

9,097,013

 

$

379,767

 

$

2,088,351

 

$

11,565,131

Table 8 – Non-Performing Assets by Geography

 

 

 

 

As of June 30,2023

(In thousands)

 

Puerto Rico

 

Virgin Islands

 

United States

 

Total

Nonaccrual loans held for investment:

 

 

 

 

 

 

 

 

Residential mortgage

 

$

20,047

 

$

5,767

 

$

7,438

 

$

33,252

Commercial mortgage

 

 

13,337

 

 

8,199

 

 

 

 

21,536

Commercial and Industrial

 

 

5,808

 

 

1,119

 

 

2,267

 

 

9,194

Construction

 

 

703

 

 

974

 

 

 

 

1,677

Consumer and finance leases

 

 

15,874

 

 

379

 

 

109

 

 

16,362

Total nonaccrual loans held for investment

 

 

55,769

 

 

16,438

 

 

9,814

 

 

82,021

OREO

 

 

27,107

 

 

4,464

 

 

 

 

31,571

Other repossessed property

 

 

5,226

 

 

168

 

 

10

 

 

5,404

Other assets (1)

 

 

2,111

 

 

 

 

 

 

2,111

Total non-performing assets (2)

 

$

90,213

 

$

21,070

 

$

9,824

 

$

121,107

Past due loans 90 days and still accruing (3)

 

$

60,964

 

$

2,108

 

$

139

 

$

63,211

 

 

 

 

 

 

 

 

 

 

 

As of March 31, 2023

(In thousands)

 

Puerto Rico

 

Virgin Islands

 

United States

 

Total

Nonaccrual loans held for investment:

 

 

 

 

 

 

 

 

Residential mortgage

 

$

22,924

 

$

6,069

 

$

7,417

 

$

36,410

Commercial mortgage

 

 

13,677

 

 

7,921

 

 

 

 

21,598

Commercial and Industrial

 

 

4,589

 

 

1,163

 

 

7,652

 

 

13,404

Construction

 

 

737

 

 

1,057

 

 

 

 

1,794

Consumer and finance leases

 

 

15,483

 

 

306

 

 

147

 

 

15,936

Total nonaccrual loans held for investment

 

 

57,410

 

 

16,516

 

 

15,216

 

 

89,142

OREO

 

 

28,323

 

 

4,539

 

 

 

 

32,862

Other repossessed property

 

 

4,620

 

 

112

 

 

11

 

 

4,743

Other assets (1)

 

 

2,203

 

 

 

 

 

 

2,203

Total non-performing assets (2)

 

$

92,556

 

$

21,167

 

$

15,227

 

$

128,950

Past due loans 90 days and still accruing (3)

 

$

72,000

 

$

2,380

 

$

 

$

74,380

 

 

 

 

 

 

 

 

 

 

 

As of December 31, 2022

(In thousands)

 

Puerto Rico

 

Virgin Islands

 

United States

 

Total

Nonaccrual loans held for investment:

 

 

 

 

 

 

 

 

Residential mortgage

 

$

28,857

 

$

6,614

 

$

7,301

 

$

42,772

Commercial mortgage

 

 

14,341

 

 

7,978

 

 

 

 

22,319

Commercial and Industrial

 

 

5,859

 

 

1,179

 

 

792

 

 

7,830

Construction

 

 

831

 

 

1,377

 

 

 

 

2,208

Consumer and finance leases

 

 

14,142

 

 

469

 

 

195

 

 

14,806

Total nonaccrual loans held for investment

 

 

64,030

 

 

17,617

 

 

8,288

 

 

89,935

OREO

 

 

28,135

 

 

3,475

 

 

31

 

 

31,641

Other repossessed property

 

 

5,275

 

 

76

 

 

29

 

 

5,380

Other assets (1)

 

 

2,202

 

 

 

 

 

 

2,202

Total non-performing assets (2)

 

$

99,642

 

$

21,168

 

$

8,348

 

$

129,158

Past due loans 90 days and still accruing (3)

 

$

76,417

 

$

4,100

 

$

 

$

80,517

(1)

Residential pass-through MBS issued by the PRHFA held as part of the available-for-sale debt securities portfolio.

(2)

Excludes PCD loans previously accounted for under ASC Subtopic 310-30 for which the Corporation made the accounting policy election of maintaining pools of loans as “units of account” both at the time of adoption of CECL on January 1, 2020 and on an ongoing basis for credit loss measurement. These loans will continue to be excluded from nonaccrual loan statistics as long as the Corporation can reasonably estimate the timing and amount of cash flows expected to be collected on the loan pools. The portion of such loans contractually past due 90 days or more amounted to $9.5 million as of June 30, 2023 (March 31, 2023 – $10.4 million; December 31, 2022 – $12.0 million).

(3)

These include rebooked loans, which were previously pooled into GNMA securities, amounting to $6.5 million as of June 30, 2023 (March 31, 2023 – $7.1 million; December 31, 2022 – $10.3 million). Under the GNMA program, the Corporation has the option but not the obligation to repurchase loans that meet GNMA’s specified delinquency criteria. For accounting purposes, the loans subject to the repurchase option are required to be reflected on the financial statements with an offsetting liability.

Table 9 – Allowance for Credit Losses on Loans and Finance Leases

 

 

 

Quarter Ended

 

Six-Month Period Ended

 

June 30,

 

March 31,

 

June 30,

 

June 30,

 

June 30,

 

2023

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

(Dollars in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance for credit losses on loans and finance leases, beginning of period

$

265,567

 

 

$

260,464

 

 

$

245,447

 

 

$

260,464

 

 

$

269,030

 

Impact of adoption of ASU 2022-02

 

 

 

 

2,116

 

 

 

 

 

 

2,116

 

 

 

 

Provision for credit losses on loans and finance leases expense (benefit)

 

20,770

 

 

 

16,256

 

 

 

12,665

 

 

 

37,026

 

 

 

(4,324

)

Net (charge-offs) recoveries of loans and finance leases:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Residential mortgage

 

(389

)

 

 

(486

)

 

 

(792

)

 

 

(875

)

 

 

(1,938

)

Commercial mortgage

 

(32

)

 

 

150

 

 

 

1,216

 

 

 

118

 

 

 

1,223

 

Commercial and Industrial

 

(6,218

)

 

 

(28

)

 

 

521

 

 

 

(6,246

)

 

 

1,266

 

Construction

 

371

 

 

 

63

 

 

 

27

 

 

 

434

 

 

 

35

 

Consumer loans and finance leases

 

(13,011

)

 

 

(12,968

)

 

 

(6,932

)

 

 

(25,979

)

 

 

(13,140

)

Net charge-offs

 

(19,279

)

 

 

(13,269

)

 

 

(5,960

)

 

 

(32,548

)

 

 

(12,554

)

Allowance for credit losses on loans and finance leases, end of period

$

267,058

 

 

$

265,567

 

 

$

252,152

 

 

$

267,058

 

 

$

252,152

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Allowance for credit losses on loans and finance leases to period end total loans held for investment

 

2.28

%

 

 

2.29

%

 

 

2.25

%

 

 

2.28

%

 

 

2.25

%

Net charge-offs (annualized) to average loans outstanding during the period

 

0.67

%

 

 

0.46

%

 

 

0.21

%

 

 

0.56

%

 

 

0.23

%

Provision for credit losses on loans and finance leases expense (benefit) to net charge-offs during the period

 

1.08x

 

 

1.23x

 

 

2.13x

 

 

1.14x

 

 

-0.34x

Table 10 – Annualized Net Charge-Offs (Recoveries) to Average Loans

 

 

Quarter Ended

 

Six-Month Period Ended

 

June 30, 2023

 

March 31, 2023

 

June 30, 2022

 

June 30, 2023

 

June 30, 2022

Residential mortgage

0.06

%

 

0.07

%

 

0.11

%

 

0.06

%

 

0.13

%

Commercial mortgage

0.01

%

 

-0.03

%

 

-0.22

%

 

-0.01

%

 

-0.11

%

Commercial and Industrial

0.87

%

 

0.00

%

 

-0.07

%

 

0.44

%

 

-0.09

%

Construction

-0.99

%

 

-0.17

%

 

-0.09

%

 

-0.59

%

 

-0.06

%

Consumer loans and finance leases

1.51

%

 

1.54

%

 

0.91

%

 

1.53

%

 

0.88

%

Total loans

0.67

%

 

0.46

%

 

0.21

%

 

0.56

%

 

0.23

%

Table 11 – Deposits

 

 

As of

 

June 30, 2023

 

March 31, 2023

 

December 31, 2022

(In thousands)

 

 

 

 

 

Time deposits

$

2,680,250

 

$

2,418,611

 

$

2,250,876

Interest-bearing saving and checking accounts

 

7,901,599

 

 

7,356,145

 

 

7,673,881

Non-interest-bearing deposits

 

5,874,261

 

 

6,024,304

 

 

6,112,884

Total deposits, excluding brokered CDs (1)

 

16,456,110

 

 

15,799,060

 

 

16,037,641

Brokered CDs

 

363,582

 

 

252,905

 

 

105,826

Total deposits

$

16,819,692

 

$

16,051,965

 

$

16,143,467

Total deposits, excluding brokered CDs and government deposits

$

13,021,598

 

$

13,125,868

 

$

13,268,585

(1)

As of June 30, 2023, March 31, 2023, and December 31, 2022, government deposits amounted to $3.4 billion, $2.7 billion, and $2.8 billion, respectively.

 

First BanCorp.

Ramon Rodriguez

Senior Vice President

Corporate Strategy and Investor Relations

[email protected]

(787) 729-8200 Ext. 82179

KEYWORDS: Caribbean Puerto Rico United States North America Florida

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo
Logo

Identiv Simplifies Cyber-Secure Access Control with Primis

Identiv Simplifies Cyber-Secure Access Control with Primis

Secure any organization with affordable, plug-and-play solutions, available on-premises or ACaaS, supporting mobile or card credentials

FREMONT, Calif.–(BUSINESS WIRE)–
Identiv, Inc. (NASDAQ: INVE), a global leader in digital security and identification in the Internet of Things (IoT), introduces Primis, a suite of access control solutions designed for every security need. Primis offers secure, affordable, and ready-to-use security solutions straight out of the box, streamlining access control for businesses of all sizes.

The suite features Primis on-premises access control, Primis Cloud, Primis Mobile, and the EG-2 controller. By transforming traditional physical access control systems into user-friendly, cyber-secure solutions, Primis simplifies security.

Ideal for small to medium-sized setups, the Primis suite ensures quick installation, minimal training, and easy maintenance. It delivers superior security and reliability at the lowest possible cost, already proven across over 500 deployments to date.

“Primis isn’t your parent’s access control. It’s designed for today’s SMBs and future-focused organizations; this is our vision for the future of access control where complexity is no barrier and where high security is accessible to everyone,” said Mike Taylor, VP Global Sales, Identiv. “With Primis, access control is always ready, making security simple and easy to use.”

The Primis suite includes:

  • Primis: On-site access control hardware and software transforms security with robust, feature-rich technology. It integrates seamlessly with IT networks, eliminating complex configurations and potential vulnerabilities, resulting in enhanced, reliable access control at a lower cost.
  • Primis Cloud: This flexible, secure access control as a service (ACaaS) offering delivers a cloud-based, subscription service version of Primis that minimizes maintenance. Housed in Identiv’s secure AWS virtual environment, Primis Cloud provides 24/7, interruption-free access control.
  • Primis Mobile: The app leverages GPS technology to replace physical credentials with an innovative mobile solution, simplifying access control management through an easy mobile enrollment process.
  • EG-2: A robust mix of power, flexibility, and security, EG-2 is a smart controller that allows door access management from anywhere. It provides a resilient solution that adapts to business needs, even in the event of server disconnections.

“Today’s launch underscores Identiv’s commitment to delivering top-tier service, security, and support to our partners,” Taylor added. “We invite potential partners to join our global network and benefit from our world-class program.”

The Primis suite is exclusively available worldwide through the Identiv Channel Alliance Network (ICAN) partner program. ICAN Partners enjoy numerous benefits, including product discounts, access to comprehensive technical support, sales leads, authorized dealer certificates, co-branded marketing materials, and instant 24/7 access to sales tools and technical resources.

Identiv’s solutions provide the highest security at the lowest cost. For more information on Identiv’s complete end-to-end portfolio, call +1 888.809.8880, contact [email protected], or book a site walk.

About Identiv

Identiv, Inc. is a global leader in digitally securing the physical world. Identiv’s platform encompasses RFID and NFC, cybersecurity, and the full spectrum of physical access, video, and audio security. Identiv is a publicly traded company, and its common stock is listed on the NASDAQ Stock Market LLC in the U.S. under the symbol “INVE.” For more information, visit identiv.com.

Identiv Media Contact:

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Hardware

MEDIA:

Logo
Logo

Masco Corporation Reports Second Quarter 2023 Results

Masco Corporation Reports Second Quarter 2023 Results

Highlights

  • Operating profit was $403 million; adjusted operating profit was $404 million

  • Operating profit margin was 18.9 percent; adjusted operating profit margin expanded 140 basis points to 19.0 percent

  • Earnings per share was $1.16 per share; adjusted earnings per share grew 3 percent to $1.19 per share

  • Entered into an agreement to acquire Sauna360 Group Oy, a strategic bolt-on that expands the Company’s spa and wellness product offerings

  • Raising expected 2023 earnings per share to be in the range of $3.48 – $3.63 per share, and on an adjusted basis, $3.50 – $3.65 per share

LIVONIA, Mich.–(BUSINESS WIRE)–
Masco Corporation (NYSE: MAS), one of the world’s leading manufacturers of branded home improvement and building products, reported its second quarter results.

2023 Second Quarter Results

  • On a reported basis, compared to second quarter 2022:

    • Net sales decreased 10 percent to $2,127 million; in local currency, net sales decreased 9 percent

    • In local currency, North American sales decreased 10 percent and international sales decreased 8 percent

    • Gross margin increased 350 basis points to 36.2 percent from 32.7 percent

    • Operating profit decreased 1 percent to $403 million from $408 million

    • Operating margin increased 160 basis points to 18.9 percent from 17.3 percent

    • Net income decreased to $1.16 per share, compared to $1.18 per share

  • Compared to second quarter 2022, results for key financial measures, as adjusted for certain items (see Exhibit A) and with a normalized tax rate of 24 percent, were as follows:

    • Gross margin increased 320 basis points to 36.2 percent from 33.0 percent

    • Operating profit decreased 2 percent to $404 million from $414 million

    • Operating margin increased 140 basis points to 19.0 percent from 17.6 percent

    • Net income increased 3 percent to $1.19 per share, compared to $1.15 per share

  • Liquidity at the end of the second quarter was $1,380 million (including availability under revolving credit facility)

  • Plumbing Products’ net sales decreased 11 percent; in local currency, net sales decreased 10 percent

  • Decorative Architectural Products’ net sales decreased 8 percent

“In the first half of the year, we demonstrated our ability to mitigate the impacts of a lower demand environment with a focus on productivity and shareholder returns,” said Masco President and CEO, Keith Allman. “In the second quarter, our pricing actions and improved operational efficiency helped drive adjusted operating profit margin expansion of 140 basis points. At the same time, we continued to execute on our balanced capital deployment strategy and returned $89 million to shareholders through dividends and share repurchases in the quarter, while announcing a strategic bolt-on with the anticipated addition of Sauna360 Group Oy to expand our spa and wellness product offerings.”

Allman continued, “As a result of our strong execution during the first half of the year, we now anticipate adjusted earnings per share in the range of $3.50 to $3.65 per share for 2023, up from our previous expectation of $3.10 to $3.40 per share. While the near-term demand environment remains challenging, the long-term fundamentals of our repair and remodel markets continue to be strong. We remain focused on investing in our brands and capabilities and maintaining strong execution. Given Masco’s strong free cash flow and disciplined capital deployment, we are well positioned to drive shareholder value creation for the long-term,” concluded Allman.

Agreement to Acquire Sauna360 Group Oy

Masco has entered into an agreement to acquire Sauna360 Group Oy, a leading global manufacturer of sauna solutions. Sauna360 Group Oy complements the Company’s spa business and will expand its wellness product offerings with the addition of the Tylö®, Helo®, Kastor®, Finnleo® and Amerec® brands. The transaction is expected to close in the third quarter, subject to regulatory approval.

Dividend Declaration

Masco’s Board of Directors declared a quarterly dividend of $0.285 per share, payable on August 28, 2023 to shareholders of record on August 11, 2023.

About Masco

Headquartered in Livonia, Michigan, Masco Corporation is a global leader in the design, manufacture and distribution of branded home improvement and building products. Our portfolio of industry-leading brands includes Behr® paint; Delta® and Hansgrohe® faucets, bath and shower fixtures; Kichler® decorative and outdoor lighting; and HotSpring® spas. We leverage our powerful brands across product categories, sales channels and geographies to create value for our customers and shareholders. For more information about Masco Corporation, visit www.masco.com.

The 2023 second quarter supplemental material, including a presentation in PDF format, is available on the Company’s website at www.masco.com.

Conference Call Details

A conference call regarding items contained in this release is scheduled for Thursday, July 27, 2023 at 8:00 a.m. ET. Participants in the call are asked to register five to ten minutes prior to the scheduled start time by dialing 888-886-7786 and from outside the U.S. at 416-764-8658. Please use the conference identification number 14959971.

The conference call will be webcast simultaneously and in its entirety through the Company’s website. Shareholders, media representatives and others interested in Masco may participate in the webcast by registering through the Investor Relations section on the Company’s website.

A replay of the call will be available on Masco’s website or by phone by dialing 877-674-7070 and from outside the U.S. at 416-764-8692. Please use the playback passcode 959971#. The telephone replay will be available approximately two hours after the end of the call and continue through August 27, 2023.

Safe Harbor Statement

This press release contains statements that reflect our views about our future performance and constitute “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “outlook,” “believe,” “anticipate,” “appear,” “may,” “will,” “should,” “intend,” “plan,” “estimate,” “expect,” “assume,” “seek,” “forecast,” and similar references to future periods. Our views about future performance involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. We caution you against relying on any of these forward-looking statements.

Our future performance may be affected by the levels of residential repair and remodel activity, and to a lesser extent, new home construction, our ability to maintain our strong brands and to develop innovative products, our ability to maintain our public reputation, our ability to maintain our competitive position in our industries, our reliance on key customers, the cost and availability of materials, our dependence on suppliers and service providers, extreme weather events and changes in climate, risks associated with our international operations and global strategies, our ability to achieve the anticipated benefits of our strategic initiatives, our ability to successfully execute our acquisition strategy and integrate businesses that we have acquired and may in the future acquire, our ability to attract, develop and retain a talented and diverse workforce, risks associated with cybersecurity vulnerabilities, threats and attacks, risks associated with our reliance on information systems and technology and the impact of the ongoing COVID-19 pandemic on our business and operations. These and other factors are discussed in detail in Item 1A. “Risk Factors” in our most recent Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and in other filings we make with the Securities and Exchange Commission. Any forward-looking statement made by us speaks only as of the date on which it was made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Unless required by law, we undertake no obligation to update publicly any forward-looking statements as a result of new information, future events or otherwise.

MASCO CORPORATION

Condensed Consolidated Statements of Operations – Unaudited

For the Three and Six Months Ended June 30, 2023 and 2022

 

(in millions, except per common share data)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

2023

 

2022

 

2023

 

2022

Net sales

$

2,127

 

 

$

2,352

 

 

$

4,106

 

 

$

4,553

 

Cost of sales

 

1,358

 

 

 

1,583

 

 

 

2,668

 

 

 

3,080

 

Gross profit

 

769

 

 

 

769

 

 

 

1,438

 

 

 

1,473

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

366

 

 

 

361

 

 

 

720

 

 

 

712

 

Operating profit

 

403

 

 

 

408

 

 

 

718

 

 

 

761

 

 

 

 

 

 

 

 

 

Other income (expense), net:

 

 

 

 

 

 

 

Interest expense

 

(28

)

 

 

(28

)

 

 

(56

)

 

 

(53

)

Other, net

 

(1

)

 

 

17

 

 

 

(3

)

 

 

16

 

 

 

(29

)

 

 

(11

)

 

 

(59

)

 

 

(37

)

Income before income taxes

 

374

 

 

 

397

 

 

 

659

 

 

 

724

 

 

 

 

 

 

 

 

 

Income tax expense

 

96

 

 

 

103

 

 

 

160

 

 

 

178

 

Net income

 

278

 

 

 

294

 

 

 

499

 

 

 

546

 

 

 

 

 

 

 

 

 

Less: Net income attributable to noncontrolling interest

 

15

 

 

 

16

 

 

 

31

 

 

 

35

 

Net income attributable to Masco Corporation

$

263

 

 

$

278

 

 

$

468

 

 

$

511

 

 

 

 

 

 

 

 

 

Income per common share attributable to Masco Corporation (diluted):

 

 

 

 

 

 

 

Net income

$

1.16

 

 

$

1.18

 

 

$

2.07

 

 

$

2.15

 

 

 

 

 

 

 

 

 

Average diluted common shares outstanding

 

226

 

 

 

233

 

 

 

226

 

 

 

237

 

 

Historical information is available on our website.

MASCO CORPORATION

Exhibit A: Reconciliations – Unaudited

For the Three and Six Months Ended June 30, 2023 and 2022

 

(dollars in millions)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

2023

 

2022

 

2023

 

2022

Gross Profit, Selling, General and Administrative Expenses, and Operating Profit Reconciliations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

2,127

 

 

$

2,352

 

 

$

4,106

 

 

$

4,553

 

 

 

 

 

 

 

 

 

Gross profit, as reported

$

769

 

 

$

769

 

 

$

1,438

 

 

$

1,473

 

Rationalization charges (income) (1)

 

1

 

 

 

6

 

 

 

(3

)

 

 

9

 

Gross profit, as adjusted

$

770

 

 

$

775

 

 

$

1,435

 

 

$

1,482

 

 

 

 

 

 

 

 

 

Gross margin, as reported

 

36.2

%

 

 

32.7

%

 

 

35.0

%

 

 

32.4

%

Gross margin, as adjusted

 

36.2

%

 

 

33.0

%

 

 

34.9

%

 

 

32.5

%

 

 

 

 

 

 

 

 

Selling, general and administrative expenses, as reported

$

366

 

 

$

361

 

 

$

720

 

 

$

712

 

Rationalization charges

 

 

 

 

 

 

 

1

 

 

 

 

Selling, general and administrative expenses, as adjusted

$

366

 

 

$

361

 

 

$

719

 

 

$

712

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses as percent of net sales, as reported

 

17.2

%

 

 

15.3

%

 

 

17.5

%

 

 

15.6

%

Selling, general and administrative expenses as percent of net sales, as adjusted

 

17.2

%

 

 

15.3

%

 

 

17.5

%

 

 

15.6

%

 

 

 

 

 

 

 

 

Operating profit, as reported

$

403

 

 

$

408

 

 

$

718

 

 

$

761

 

Rationalization charges (income) (1)

 

1

 

 

 

6

 

 

 

(2

)

 

 

9

 

Operating profit, as adjusted

$

404

 

 

$

414

 

 

$

716

 

 

$

770

 

 

 

 

 

 

 

 

 

Operating margin, as reported

 

18.9

%

 

 

17.3

%

 

 

17.5

%

 

 

16.7

%

Operating margin, as adjusted

 

19.0

%

 

 

17.6

%

 

 

17.4

%

 

 

16.9

%

(1)

Represents income for the six months ended June 30, 2023 due to the sale of excess and obsolete inventory that was related to a rationalization activity, partially offset by rationalization charges.

 

Historical information is available on our website.

MASCO CORPORATION

Exhibit A: Reconciliations – Unaudited

For the Three and Six Months Ended June 30, 2023 and 2022

 

(in millions, except per common share data)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

2023

 

2022

 

2023

 

2022

Income Per Common Share Reconciliations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before income taxes, as reported

$

374

 

 

$

397

 

 

$

659

 

 

$

724

 

Rationalization charges (income) (1)

 

1

 

 

 

6

 

 

 

(2

)

 

 

9

 

Fair value adjustment to contingent earnout obligation (2)

 

 

 

 

(28

)

 

 

 

 

 

(24

)

(Gain) on sale of business (3)

 

 

 

 

 

 

 

 

 

 

(2

)

Realized (gains) from private equity funds

 

 

 

 

 

 

 

(1

)

 

 

 

Income before income taxes, as adjusted

 

375

 

 

 

375

 

 

 

656

 

 

 

707

 

Tax at 24% rate

 

(90

)

 

 

(90

)

 

 

(157

)

 

 

(170

)

Less: Net income attributable to noncontrolling interest

 

15

 

 

 

16

 

 

 

31

 

 

 

35

 

Net income, as adjusted

$

270

 

 

$

269

 

 

$

468

 

 

$

502

 

 

 

 

 

 

 

 

 

Net income per common share, as adjusted

$

1.19

 

 

$

1.15

 

 

$

2.07

 

 

$

2.12

 

 

 

 

 

 

 

 

 

Average diluted common shares outstanding

 

226

 

 

 

233

 

 

 

226

 

 

 

237

 

(1)

Represents income for the six months ended June 30, 2023 due to the sale of excess and obsolete inventory that was related to a rationalization activity, partially offset by rationalization charges.

(2)

Represents income for the three and six months ended June 30, 2022 from the revaluation of contingent consideration related to a prior acquisition.

(3)

Represents a pre-tax post-closing gain related to the finalization of working capital items related to the divestiture of Hüppe GmbH for the six months ended June 30, 2022.

Outlook for the Year Ended December 31, 2023

 

 

 

Year Ended December 31, 2023

 

Low End

 

High End

Income Per Common Share Reconciliation

 

 

 

 

 

 

 

Net income per common share

$

3.48

 

$

3.63

Rationalization charges

 

0.02

 

 

0.02

Net income per common share, as adjusted

$

3.50

 

$

3.65

 

Historical information is available on our website.

MASCO CORPORATION

Condensed Consolidated Balance Sheets and Other Financial Data – Unaudited

June 30, 2023 and December 31, 2022

 

(dollars in millions)

 

 

June 30, 2023

 

December 31, 2022

Balance Sheet

 

 

 

 

Assets

 

 

 

 

Current assets:

 

 

 

 

Cash and cash investments

 

$

380

 

$

452

 

Receivables

 

 

1,371

 

 

1,149

 

Inventories

 

 

1,144

 

 

1,236

 

Prepaid expenses and other

 

 

112

 

 

109

 

Total current assets

 

 

3,007

 

 

2,946

 

 

 

 

 

 

Property and equipment, net

 

 

1,063

 

 

975

 

Goodwill

 

 

540

 

 

537

 

Other intangible assets, net

 

 

337

 

 

350

 

Operating lease right-of-use assets

 

 

264

 

 

266

 

Other assets

 

 

97

 

 

113

 

Total assets

 

$

5,308

 

$

5,187

 

 

 

 

 

 

Liabilities

 

 

 

 

Current liabilities:

 

 

 

 

Accounts payable

 

$

958

 

$

877

 

Notes payable

 

 

79

 

 

205

 

Accrued liabilities

 

 

712

 

 

807

 

Total current liabilities

 

 

1,749

 

 

1,889

 

 

 

 

 

 

Long-term debt

 

 

2,946

 

 

2,946

 

Noncurrent operating lease liabilities

 

 

252

 

 

255

 

Other liabilities

 

 

333

 

 

339

 

Total liabilities

 

 

5,280

 

 

5,429

 

 

 

 

 

 

Redeemable noncontrolling interest

 

 

21

 

 

20

 

 

 

 

 

 

Equity

 

 

7

 

 

(262

)

Total liabilities and equity

 

$

5,308

 

$

5,187

 

 

As of June 30,

 

2023

 

2022

Other Financial Data

 

 

 

Working capital days

 

 

 

Receivable days

 

54

 

 

 

52

 

Inventory days

 

80

 

 

 

88

 

Payable days

 

70

 

 

 

67

 

Working capital

$

1,557

 

 

$

1,660

 

Working capital as a % of sales (LTM)

 

18.9

%

 

 

18.9

%

 

Historical information is available on our website.

MASCO CORPORATION

Condensed Consolidated Statements of Cash Flows and Other Financial Data – Unaudited

For the Six Months Ended June 30, 2023 and 2022

 

(dollars in millions)

 

Six Months Ended June 30,

 

2023

 

2022

Cash Flows From (For) Operating Activities:

 

 

 

Cash provided by operating activities

$

632

 

 

$

662

 

Working capital changes

 

(184

)

 

 

(488

)

Net cash from operating activities

 

448

 

 

 

174

 

 

 

 

 

Cash Flows From (For) Financing Activities:

 

 

 

Purchase of Company common stock

 

(81

)

 

 

(914

)

Cash dividends paid

 

(129

)

 

 

(131

)

Dividends paid to noncontrolling interest

 

(49

)

 

 

 

Proceeds from short-term borrowings

 

77

 

 

 

 

Proceeds from term loan

 

 

 

 

500

 

Payment of term loan

 

(200

)

 

 

 

Proceeds from the exercise of stock options

 

23

 

 

 

1

 

Employee withholding taxes paid on stock-based compensation

 

(23

)

 

 

(17

)

Decrease in debt, net

 

(4

)

 

 

(7

)

Net cash for financing activities

 

(386

)

 

 

(568

)

 

 

 

 

Cash Flows From (For) Investing Activities:

 

 

 

Capital expenditures

 

(133

)

 

 

(70

)

Other, net

 

(4

)

 

 

(4

)

Net cash for investing activities

 

(137

)

 

 

(74

)

 

 

 

 

Effect of exchange rate changes on cash and cash investments

 

3

 

 

 

(18

)

 

 

 

 

Cash and Cash Investments:

 

 

 

Decrease for the period

 

(72

)

 

 

(486

)

At January 1

 

452

 

 

 

926

 

At June 30

$

380

 

 

$

440

 

 

As of June 30,

 

2023

 

2022

Liquidity

 

 

 

Cash and cash investments

$

380

 

$

440

Revolver availability

 

1,000

 

 

1,000

Total Liquidity

$

1,380

 

$

1,440

 

Historical information is available on our website.

MASCO CORPORATION

Segment Data – Unaudited

For the Three and Six Months Ended June 30, 2023 and 2022

 

(dollars in millions)

 

Three Months Ended June 30,

 

 

 

Six Months Ended June 30,

 

 

 

2023

 

2022

 

Change

 

2023

 

2022

 

Change

Plumbing Products

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

1,225

 

 

$

1,373

 

 

(11

)%

 

$

2,447

 

 

$

2,732

 

 

(10

)%

 

 

 

 

 

 

 

 

 

 

 

 

Operating profit, as reported

$

244

 

 

$

238

 

 

 

 

$

450

 

 

$

466

 

 

 

Operating margin, as reported

 

19.9

%

 

 

17.3

%

 

 

 

 

18.4

%

 

 

17.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rationalization charges (income)

 

1

 

 

 

 

 

 

 

 

(3

)

 

 

 

 

 

Operating profit, as adjusted

 

245

 

 

 

238

 

 

 

 

 

447

 

 

 

466

 

 

 

Operating margin, as adjusted

 

20.0

%

 

 

17.3

%

 

 

 

 

18.3

%

 

 

17.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

25

 

 

 

25

 

 

 

 

 

50

 

 

 

49

 

 

 

EBITDA, as adjusted

$

270

 

 

$

263

 

 

 

 

$

497

 

 

$

515

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Decorative Architectural Products

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

902

 

 

$

979

 

 

(8

)%

 

$

1,659

 

 

$

1,821

 

 

(9

)%

 

 

 

 

 

 

 

 

 

 

 

 

Operating profit, as reported

$

180

 

 

$

192

 

 

 

 

$

312

 

 

$

347

 

 

 

Operating margin, as reported

 

20.0

%

 

 

19.6

%

 

 

 

 

18.8

%

 

 

19.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rationalization charges

 

 

 

 

6

 

 

 

 

 

1

 

 

 

8

 

 

 

Accelerated depreciation related to rationalization activity

 

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

Operating profit, as adjusted

 

180

 

 

 

198

 

 

 

 

 

313

 

 

 

356

 

 

 

Operating margin, as adjusted

 

20.0

%

 

 

20.2

%

 

 

 

 

18.9

%

 

 

19.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

9

 

 

 

9

 

 

 

 

 

17

 

 

 

17

 

 

 

EBITDA, as adjusted

$

189

 

 

$

207

 

 

 

 

$

330

 

 

$

373

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

2,127

 

 

$

2,352

 

 

(10

)%

 

$

4,106

 

 

$

4,553

 

 

(10

)%

 

 

 

 

 

 

 

 

 

 

 

 

Operating profit, as reported – segment

$

424

 

 

$

430

 

 

 

 

$

762

 

 

$

813

 

 

 

General corporate expense, net

 

(21

)

 

 

(22

)

 

 

 

 

(44

)

 

 

(52

)

 

 

Operating profit, as reported

 

403

 

 

 

408

 

 

 

 

 

718

 

 

 

761

 

 

 

Operating margin, as reported

 

18.9

%

 

 

17.3

%

 

 

 

 

17.5

%

 

 

16.7

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rationalization charges (income) – segment

 

1

 

 

 

6

 

 

 

 

 

(2

)

 

 

8

 

 

 

Accelerated depreciation related to rationalization activity – segment

 

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

Operating profit, as adjusted

 

404

 

 

 

414

 

 

 

 

 

716

 

 

 

770

 

 

 

Operating margin, as adjusted

 

19.0

%

 

 

17.6

%

 

 

 

 

17.4

%

 

 

16.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization – segment

 

34

 

 

 

34

 

 

 

 

 

67

 

 

 

66

 

 

 

Depreciation and amortization – other

 

1

 

 

 

2

 

 

 

 

 

3

 

 

 

4

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EBITDA, as adjusted

$

439

 

 

$

450

 

 

 

 

$

786

 

 

$

840

 

 

 

 

Historical information is available on our website.

MASCO CORPORATION

North American and International Data – Unaudited

For the Three and Six Months Ended June 30, 2023 and 2022

 

(dollars in millions)

 

Three Months Ended June 30,

 

 

 

Six Months Ended June 30,

 

 

 

2023

 

2022

 

Change

 

2023

 

2022

 

Change

North American

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

1,718

 

 

$

1,905

 

 

(10

)%

 

$

3,273

 

 

$

3,639

 

 

(10

)%

 

 

 

 

 

 

 

 

 

 

 

 

Operating profit, as reported

$

358

 

 

$

356

 

 

 

 

$

624

 

 

$

656

 

 

 

Operating margin, as reported

 

20.8

%

 

 

18.7

%

 

 

 

 

19.1

%

 

 

18.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rationalization charges (income)

 

1

 

 

 

6

 

 

 

 

 

(2

)

 

 

8

 

 

 

Accelerated depreciation related to rationalization activity

 

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

Operating profit, as adjusted

 

359

 

 

 

362

 

 

 

 

 

622

 

 

 

665

 

 

 

Operating margin, as adjusted

 

20.9

%

 

 

19.0

%

 

 

 

 

19.0

%

 

 

18.3

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

22

 

 

 

23

 

 

 

 

 

43

 

 

 

43

 

 

 

EBITDA, as adjusted

$

381

 

 

$

385

 

 

 

 

$

665

 

 

$

708

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

International

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

409

 

 

$

447

 

 

(9

)%

 

$

833

 

 

$

914

 

 

(9

)%

 

 

 

 

 

 

 

 

 

 

 

 

Operating profit, as reported

$

66

 

 

$

74

 

 

 

 

$

138

 

 

$

157

 

 

 

Operating margin, as reported

 

16.1

%

 

 

16.6

%

 

 

 

 

16.6

%

 

 

17.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

12

 

 

 

11

 

 

 

 

 

24

 

 

 

23

 

 

 

EBITDA

$

78

 

 

$

85

 

 

 

 

$

162

 

 

$

180

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

2,127

 

 

$

2,352

 

 

(10

)%

 

$

4,106

 

 

$

4,553

 

 

(10

)%

 

 

 

 

 

 

 

 

 

 

 

 

Operating profit, as reported – segment

$

424

 

 

$

430

 

 

 

 

$

762

 

 

$

813

 

 

 

General corporate expense, net

 

(21

)

 

 

(22

)

 

 

 

 

(44

)

 

 

(52

)

 

 

Operating profit, as reported

 

403

 

 

 

408

 

 

 

 

 

718

 

 

 

761

 

 

 

Operating margin, as reported

 

18.9

%

 

 

17.3

%

 

 

 

 

17.5

%

 

 

16.7

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Rationalization charges (income) – segment

 

1

 

 

 

6

 

 

 

 

 

(2

)

 

 

8

 

 

 

Accelerated depreciation related to rationalization activity – segment

 

 

 

 

 

 

 

 

 

 

 

 

1

 

 

 

Operating profit, as adjusted

 

404

 

 

 

414

 

 

 

 

 

716

 

 

 

770

 

 

 

Operating margin, as adjusted

 

19.0

%

 

 

17.6

%

 

 

 

 

17.4

%

 

 

16.9

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization – segment

 

34

 

 

 

34

 

 

 

 

 

67

 

 

 

66

 

 

 

Depreciation and amortization – other

 

1

 

 

 

2

 

 

 

 

 

3

 

 

 

4

 

 

 

EBITDA, as adjusted

$

439

 

 

$

450

 

 

 

 

$

786

 

 

$

840

 

 

 

 

Historical information is available on our website.

 

David Chaika

Interim Chief Financial Officer

313.792.5500

[email protected]

KEYWORDS: United States North America Michigan

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Landscape Interior Design Home Goods Building Systems Retail Other Construction & Property Residential Building & Real Estate

MEDIA:

Logo
Logo

Nexstar Media Group Declares Quarterly Cash Dividend of $1.35 Per Share

Nexstar Media Group Declares Quarterly Cash Dividend of $1.35 Per Share

IRVING, Texas–(BUSINESS WIRE)–
Nexstar Media Group, Inc. (NASDAQ: NXST) announced today that its Board of Directors declared a quarterly cash dividend of $1.35 per share of its common stock. The dividend is payable on Thursday, August 24, 2023, to shareholders of record on Thursday, August 10, 2023.

While the Company intends to pay regular quarterly cash dividends for the foreseeable future, all subsequent dividends will be reviewed quarterly and declared by the Board of Directors at its discretion.

About Nexstar Media Group, Inc.

Nexstar Media Group, Inc. (NASDAQ: NXST) is a leading diversified media company that produces and distributes engaging local and national news, sports and entertainment content across television, streaming and digital platforms, including more than 300,000 hours of news, sports, and entertainment programming each year. Nexstar owns America’s largest local broadcasting group comprised of top network affiliates, with 200 owned or partner stations in 116 U.S. markets reaching 212 million people. Nexstar’s national television properties include The CW, America’s fifth major broadcast network, NewsNation, America’s fastest-growing national news and entertainment cable network reaching 70 million television homes, popular entertainment multicast networks Antenna TV and Rewind TV, and a 31.3% ownership stake in TV Food Network. The Company’s portfolio of digital assets, including The Hill and BestReviews, are collectively a Top 10 U.S. digital news and information property. In addition to delivering exceptional content and service to our communities, Nexstar provides premium multiplatform and video-on-demand advertising opportunities at scale for businesses and brands seeking to leverage the strong consumer engagement of our compelling content offering. For more information, please visit nexstar.tv.

Investor:

Lee Ann Gliha

Executive Vice President and Chief Financial Officer

Nexstar Media Group, Inc.

972/373-8800

Joseph Jaffoni, Rich Land, James Leahy

JCIR

212/835-8500 or [email protected]

Media:

Gary Weitman

EVP and Chief Communications Officer

972/373-8800

[email protected]

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Software Banking Media Entertainment Professional Services Apps/Applications Technology TV and Radio Audio/Video Communications Finance Telecommunications

MEDIA:

Logo
Logo

Bread Financial™ Provides Performance Update for June 2023

Bread Financial Provides Performance Update for June 2023

COLUMBUS, Ohio–(BUSINESS WIRE)–Bread Financial Holdings, Inc. (NYSE: BFH), a tech-forward financial services company that provides simple, personalized payment, lending and saving solutions, provided a performance update. The following tables present the Company’s net loss rate and delinquency rate for the periods indicated.

 

For the

month ended

June 30, 2023

 

For the

three months ended

June 30, 2023

 

(dollars in millions)

End-of-period credit card and other loans

$

17,962

 

 

$

17,962

 

Average credit card and other loans

$

17,623

 

 

$

17,652

 

Year-over-year change in average credit card and other loans

 

2

%

 

 

4

%

Net principal losses(1)

$

113

 

 

$

351

 

Net loss rate(1)

 

7.7

%

 

 

8.0

%

 

As of

June 30, 2023

 

As of

June 30, 2022

 

(dollars in millions)

30 days + delinquencies – principal

$

926

 

 

$

737

 

Period ended credit card and other loans – principal

$

16,728

 

 

$

16,825

 

Delinquency rate

 

5.5

%

 

 

4.4

%

________________________________________________
(1)

As previously communicated, the month and three months ended June 30, 2023 Net principal losses and Net loss rate were impacted by the transition of our credit card processing services.

About Bread Financial™

Bread Financial™(NYSE: BFH) is a tech-forward financial services company providing simple, personalized payment, lending and saving solutions. The company creates opportunities for its customers and partners through digitally enabled choices that offer ease, empowerment, financial flexibility and exceptional customer experiences. Driven by a digital-first approach, data insights and white-label technology, Bread Financial delivers growth for its partners through a comprehensive suite of payment solutions that includes private label and co-brand credit cards and Bread Pay™ buy now, pay later products. Bread Financial also offers direct-to-consumer products that give customers more access, choice and freedom through its branded Bread Cashback™ American Express® Credit Card and Bread Savings™ products.

Headquartered in Columbus, Ohio, Bread Financial is powered by its 7,500+ global associates and is committed to sustainable business practices. To learn more about Bread Financial, visit BreadFinancial.com or follow us on Facebook, LinkedIn, Twitter and Instagram.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements give our expectations or forecasts of future events and can generally be identified by the use of words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “project,” “plan,” “likely,” “may,” “should” or other words or phrases of similar import. Similarly, statements that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding, and the guidance we give with respect to, our anticipated operating or financial results, future financial performance and outlook, future dividend declarations, and future economic conditions.

We believe that our expectations are based on reasonable assumptions. Forward-looking statements, however, are subject to a number of risks and uncertainties that are difficult to predict and, in many cases, beyond our control. Accordingly, our actual results could differ materially from the projections, anticipated results or other expectations expressed in this release, and no assurances can be given that our expectations will prove to have been correct. Factors that could cause the outcomes to differ materially include, but are not limited to, the following: macroeconomic conditions, including market conditions, inflation, rising interest rates, unemployment levels and the increased probability of a recession, and the related impact on consumer payment rates, savings rates and other behavior; global political and public health events and conditions, including the ongoing war in Ukraine and the continuing effects of the global COVID-19 pandemic; future credit performance, including the level of future delinquency and write-off rates; the loss of, or reduction in demand from, significant brand partners or customers in the highly competitive markets in which we compete; the concentration of our business in U.S. consumer credit; inaccuracies in the models and estimates on which we rely, including the amount of our Allowance for credit losses and our credit risk management models; the inability to realize the intended benefits of acquisitions, dispositions and other strategic initiatives; our level of indebtedness and ability to access financial or capital markets; pending and future legislation, regulation, supervisory guidance, and regulatory and legal actions, including, but not limited to, those related to financial regulatory reform and consumer financial services practices, as well as any such actions with respect to late fees, interchange fees or other charges; impacts arising from or relating to the transition of our credit card processing services to third party service providers that we completed in 2022; failures or breaches in our operational or security systems, including as a result of cyberattacks, unanticipated impacts from technology modernization projects or otherwise; and any tax liability, disputes or other adverse impacts arising out of or relating to the spinoff of our former LoyaltyOne segment or the recent bankruptcy filings of Loyalty Ventures Inc. and certain of its subsidiaries. The foregoing factors, along with other risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements, are described in greater detail under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the most recently ended fiscal year, which may be updated in Item 1A of, or elsewhere in, our Quarterly Reports on Form 10-Q filed for periods subsequent to such Form 10-K. Our forward-looking statements speak only as of the date made, and we undertake no obligation, other than as required by applicable law, to update or revise any forward-looking statements, whether as a result of new information, subsequent events, anticipated or unanticipated circumstances or otherwise.

Brian Vereb — Investor Relations

[email protected]

Susan Haugen — Investor Relations

[email protected]

Rachel Stultz — Media

[email protected]

KEYWORDS: Ohio United States North America

INDUSTRY KEYWORDS: Fintech Professional Services Finance

MEDIA:

Logo
Logo